

# **The Michigan Trauma Quality Improvement Program**

**Ypsilanti, MI  
February 10, 2015**



# Disclosures

- ◆ Salary Support for MTQIP from BCBSM
  - Mark Hemmila
  - Judy Mikhail
  - Jill Jakubus

# Welcome/Introductions

- ◆ New Participants
  - Jonathan Saxe MD, TPD Sinai-Grace

# Welcome/Introductions

## ◆ Guests

- BCBS-Michigan
- Virginia Commonwealth University
- Wake Forest University
- Digital Innovation



# Welcome/Introductions

- ◆ BCBS-Michigan

- David Share, MD, Senior Vice President, Health Care Value
- Rozanne Darland, CQI Program Manager
- Marc Cohen, CQI Program Manager

# Welcome/Introductions

- ◆ Wake Forest University
  - Dr. Michael Chang, MD Associate Medical Director, Executive Director Trauma and Acute Care Surgery
  - Cynthia Mastropieri, Trauma Program Manager
- ◆ Virginia Commonwealth University
  - Dr. Guilherme Campos, MD PhD
  - Mary Beth Camacho, Associate Administrator
  - Luke Wolfe, MS

# Welcome/Introductions

- ◆ Digital Innovation

- John Kutcher, Chief Executive Officer

- ◆ Speakers

- Pauline Park, MD
  - James Montie, MD
  - Susan Linsell, MHSA

# ACS-TQIP

- ◆ Michigan Report
  - Executing contract for 2015 and 2016
  - Frequency
    - ◆ Two outcome reports per year
    - ◆ One custom report agreed on by TQIP and MTQIP
- ◆ No Invoices
  - 2015
  - 2016

# Data Submission

## ◆ DI

- XML written
- Server configuration and software install
- Test data
- V5 Report Writer Files, MTQIP tab Installs

## ◆ February Submission

- 7/1/2013 to 10/31/2014 (minimum)

## ◆ ArborMetrix Website

- Aim for 1 month turnaround
- Data submitted 10/3 available mid-November

# Survey Results

- ◆ Surgeons n=14, TPM n=19
- ◆ Regional Reports
  - 94% Yes
- ◆ MTQIP RN Data abstractor
  - 94% Yes
- ◆ Retain individual PI project (MTQIP data)
  - 70% Yes
- ◆ Collaborative wide PI project (Aggregate)
  - 88% Yes

# Future Meetings

- ◆ Spring (MCOT)
  - Wednesday May 13, 2015
  - Grand Rapids, Amway Grand Plaza Hotel
- ◆ Spring (Registrars)
  - Wednesday June 2, 2015
  - Ann Arbor, NCRC
- ◆ Fall
  - Tuesday October 13, 2015
  - Ypsilanti, EMU Marriott Conference Center
- ◆ Neurosurgery?

# IVC Filters

**Mark Hemmila, MD**





# IVC Filters

- ◆ MTQIP Data
  - 1/1/2010 to 9/30/2014
  - ICD9 Procedure Code 38.7
- ◆ Exclusions
  - No signs of life
  - ISS < 9
  - Hospital days < 3

	<b>N</b>	<b>%</b>
<b>None</b>	<b>38,315</b>	<b>97.4</b>
<b>IVC Filter</b>	<b>1,013</b>	<b>2.6</b>
<b>No VTE</b>	<b>38,424</b>	<b>97.7</b>
<b>VTE</b>	<b>904</b>	<b>2.3</b>
<b>No PE</b>	<b>39,057</b>	<b>99.3</b>
<b>PE</b>	<b>271</b>	<b>0.7</b>
<b>No DVT</b>	<b>38,626</b>	<b>98.2</b>
<b>DVT</b>	<b>702</b>	<b>1.8</b>
<b>Alive</b>	<b>37,912</b>	<b>96.4</b>
<b>Dead</b>	<b>1,416</b>	<b>3.6</b>

# IVC Filters


- ◆ Exclude if

- IVC Filter Placement Date > VTE Event Date
  - ◆ 161 patients
- IVC Filter Placed and VTE, but IVC Filter or VTE Event Date unknown
  - ◆ 53 patients


	<b>N</b>	<b>%</b>
<b>None</b>	<b>38,315</b>	<b>98.0</b>
<b>IVC Filter</b>	<b>799</b>	<b>2.0</b>
<b>No VTE</b>	<b>38,424</b>	<b>98.2</b>
<b>VTE</b>	<b>690</b>	<b>1.8</b>
<b>Alive</b>	<b>37,708</b>	<b>96.4</b>
<b>Dead</b>	<b>1,406</b>	<b>3.6</b>

	<b>IVC Filter N</b>	<b>IVC Filter Y</b>
<b>No VTE</b>	<b>37,683</b>	<b>741</b>
<b>VTE</b>	<b>632 (1.6%)</b>	<b>58 (7.4%)</b>

# Risk and Reliability Adjusted IVC Filter Use





# Risk and Reliability Adjusted IVC Filter Use



# Quartiles


	Quartile			
	1	2	3	4
No IVC Filter	10,302	8,512	12,251	7,250
IVC Filter	68	112	266	353
	0.7%	1.3%	2.1%	4.6%

# Mortality






# Risk and Reliability Adjusted IVC Filter Use



1/1/10 to 9/30/14

## Risk and Reliability Adjusted IVC Filter Use



3/1/13 to 9/30/14

## Next Steps

- ◆ Criteria for VTE prophylaxis?
- ◆ Criteria for IVC filter insertion?
- ◆ Appropriateness?
- ◆ Is this a group project?

# **MTQIP Reports**

**Mark Hemmila, MD**



# Confidentiality Agreement

- ◆ Everyone signs a confidentiality agreement for entry to the meeting
- ◆ Every meeting
- ◆ No photographs
- ◆ Reports distributed

# Confidentiality Agreement

The following examples are to be considered privileged and confidential information and should be discussed only within the confines of the MTQIP Quality Collaborative meetings.

- ◆ Any and all patient information.
- ◆ Any and all patient identifiers which are considered privileged and protected health information as defined by current HIPPA laws.
- ◆ Any specific Michigan trauma case information.
- ◆ Any information discussed regarding a specific MTQIP site outcome.
- ◆ Any reference to a specific MTQIP site result or analysis.
- ◆ All trauma data presented including but not limited to Composite Metrics.

# **Confidentiality Agreement**

By signing this document, I agree to protect the confidentiality of all information discussed at this meeting and take steps to safeguard against any disclosure of privileged information that may have been discussed. I understand that any violation of confidentiality may result in my personal removal from participation in the project as well as the removal of the hospital site I represent.

# Hospitals Submitting Extra Data

- ◆ Minimum Range 3/13 to 4/14
- ◆ Centers submitting extra data ( $\geq 5/1/14$ )



# Hospital Metrics



# MTQIP 2014 Hospital Metrics

- ◆ Participation 70%
  - Data Submission
  - Surgeon Lead
  - Trauma Program Manager/Registrar
  - Site-specific QI project
  - Presentation/Use of MTQIP data
- ◆ Performance 30%
  - Data Validation
  - Massive Transfusion Protocol
  - VTE Prophylaxis

2014 MTQIP Hospital Metrics				
Measure	Weight	Measure Description	Points (Existing Participants)	Points (New Participants)
PARTICIPATION (70%)				
#1	10	<b>Data Submission</b>		
		On time 3 of 3 times	10	10
		On time 2 of 3 times	5	5
		On time 1 of 3 times	0	0
#2	20	<b>Meeting Participation – Surgeon Lead</b>		
		Participated in 3 of 3 meetings	20	20
		Participated in 2 of 3 meetings	10	10
		Participated in 1 of 3 meetings	5	5
		No participation	0	0
#3	20	<b>Meeting Participation – Trauma Manager/Registrar (Avg)</b>		
		Participated in 3 of 3 meetings	20	20
		Participated in 2 of 3 meetings	10	10
		Participated in 1 of 3 meetings	5	5
		No participation	0	0
#4	10	<b>Site Specific Quality Improvement Project Implementation</b>		
		Project data submitted	10	10
		Project data not submitted	0	0
#5	10	<b>Surgeon Lead Presents MTQIP Reports at Hospital Meetings</b>		
		Presented at 3 meetings	10	10
		Presented at 2 meetings	8	8
		Presented at 1 meeting	5	5
		Did not present	0	0
		*Signed attestation required		

# #1 Data Submission

10 Points

---

5 Points

---

## #2 Meeting Participation – Surgeon Lead

20 Points

---

10 Points

---

5 Points

---

## **#3 Meeting Participation – Program Manager/Registrar**

**20 Points**

---

**10 Points**

---

## **#4 Site Specific Quality Improvement Project**

**10 Points**

---

## **#5 Presentation of MTQIP Reports at Hospital Meetings**

**10 Points**

---

**0 Points**

---



# Performance

PERFORMANCE (30%)						
#6	10	Accuracy of Data				na
			Visit #1	Visit #2 or More		
		5 star validation	0-4.5%	0-4.5%	10	
		4 star validation	4.6-5.5%	4.6-5.5%	8	
		3 star validation	5.6-8.0%	5.6-7.0%	5	
		2 star validation	8.1-9.0%	7.1-8.0%	3	
		1 star validation	> 9%	> 8.0%	0	
#7	10	Massive Transfusion (defined as ≥ 4 u PRBC in first 4 hours): Mean PRBC to Plasma Ratio for first 4 hours of admission				na
		≤ 1.5			10	
		1.6 - 2.5			7.5	
		> 2.5			5	
		> 3.0			0	
#8	10	Timely VTE Prophylaxis (< 48 hours of admission)				na
		> 50%			10	
		≥ 40%			5	
		< 40%			0	

## #6 Accuracy of Data

10 Points

---

8 Points

---

5 Points

---

3 Points

---

0 Points

---


**Blood Products (2/1/13 to 9/30/14)**

Inclusion:

PRBC 4hrs  $\geq$  4 units

<u>Trauma Center</u>	<u>N Patients</u>	<u>Ratio</u> <u>PRBC/FFP</u> <u>4 hrs</u>	<u>N Ratio</u> <u>PRBC/FFP</u> <u>4 hrs <math>\leq</math> 3</u>	<u>N Ratio</u> <u>PRBC/FFP</u> <u>4 hrs <math>\leq</math> 2.5</u>	<u>N Ratio</u> <u>PRBC/FFP</u> <u>4 hrs <math>\leq</math> 1.5</u>	<u>Ratio</u> <u>PRBC/FFP</u> <u>24 hrs</u>	<u>N Ratio</u> <u>PRBC/FFP</u> <u>24 hrs <math>\leq</math> 2.0</u>	<u>N Ratio</u> <u>PRBC/FFP</u> <u>24 hrs <math>\leq</math> 1.5</u>	<u>Dead</u>
18	26	1.1	25	25	22	1.2	25	20	9
20	7	1.2	5	5	4	0.8	2	2	2
2	8	1.4	5	5	4	1.4	6	4	2
22	4	1.5	4	4	2	2.0	2	2	2
17	18	1.6	13	11	9	1.6	12	10	7
10	24	1.7	19	18	16	1.5	20	19	8
14	18	1.7	12	12	7	1.7	12	8	10
19	12	1.7	7	6	3	1.7	8	3	4
6	4	1.8	2	2	1	3.0	2	1	2
8	14	1.9	11	9	5	2.3	8	6	6
3	18	1.9	11	10	8	1.9	11	7	8
11	21	1.9	15	15	8	1.9	12	8	8
27	24	1.9	17	15	10	2.0	14	11	12
5	14	2.1	11	9	3	2.3	6	3	8
23	6	2.2	3	2	0	2.3	2	0	3
24	1	2.2	1	1	0	0.9	1	1	0
21	35	2.5	19	14	7	2.6	15	7	15
7	20	2.6	12	12	4	2.3	10	5	7
1	9	2.8	3	3	0	2.7	2	0	4
13	16	2.9	10	9	4	2.1	6	3	2
15	42	3.1	21	16	4	2.7	17	9	14
4	16	3.2	9	6	3	3.2	6	3	8
16	8	3.3	5	4	2	3.3	3	2	4
9	2	3.7	0	0	0	3.3	0	0	1
Total	367	1.8	240	213	126	1.7	202	134	146

# Blood Product Ratio in first 4 hrs if $\geq 4$ uPRBCs



2/1/13 to 9/30/14

# MTQIP 2014 Hospital Metrics

## ◆ Massive Transfusion

- $\geq 4$  units PRBC's in first 4 hrs
- Average of ratio for each patient
- 7/1/13 to 9/30/14

### **Ratio PRBC/FFP**

### **Points**

< 1.5	10
1.6 – 2.5	7.5
2.6 – 3.0	5
> 3.0	0

## **#7 MTP – Mean PRBC to Plasma ratio first 4 hrs**

**10 Points**

---

**7.5 Points**

---


**5 Points**

---


**0 Points**

---

# VTE Prophylaxis



# Rate of VTE Prophylaxis by 48 hrs



3/1/13 to 9/30/14



# VTE Prophylaxis

- ◆ Admit Trauma Service
  - In hospital with no VTE pro = non-Event
  - Discharge Home in 48 hrs = Event
  - VTE Prophylaxis in 48 hrs = Event
  - 3/1/13 to 9/30/14 or 7/1/13 to 9/30/14
- ◆ Rate
  - $\geq 50\%$  (10 points)
  - $\geq 40\%$  (5 points)
  - 0 – 39% (0 points)

## #8 Timely VTE Prophylaxis

**10 Points**

---

**0 Points**

---


**5 Points**

---

# 2014 Hospital Metrics - Totals

Hospital	Points (100 Max)
----------	------------------

## 2014 MTQIP Hospital Metrics - Totals



# It's not perfect – What I learned

- ◆ Attention grabber
- ◆ Getting points is achievable by all
- ◆ Data problems
  - Scoring due 1<sup>st</sup> Quarter
  - Data submission in Oct and Feb
  - Cardiac goes back one year from Sept/Oct
- ◆ ~~Reactionary~~ / Thoughtful
- ◆ Perceptions vs. Reality e.g. Blood

# Resources for Optimal Care of the Injured Patient

## Chapter 15 – Trauma Registry

### Outcomes Measurement

Outcomes measurements describe the results of intervention and management. Positive patient outcomes result from effective and efficient systems of care. Outcomes measurement focuses on a wide variety of clinical results, including the quality of life and the level of function achieved by patients who survive trauma. The most effective use of outcomes measurement is through a rigorous process based on standardized data and risk adjustment. Such risk-adjusted benchmarking processes may occur at the regional, state, or national level. The ACS TQIP provides the opportunity for such outcomes measurement. **All trauma centers must use a risk-adjusted benchmarking system to measure performance and outcomes (CD 15–5).**

# Resources for Optimal Care of the Injured Patient

## Chapter 16 – PIPS

### Clinical Practice Guidelines, Protocols, and Algorithms

Trauma programs should seek to reduce unnecessary variation in the care they provide. To achieve this goal, a trauma program must use **clinical practice guidelines, protocols, and algorithms** derived from evidenced-based validated resources (CD 16–4). In areas where there is an absence of such resources, consensus-based institutional guidelines should be established according to the most current available peer-reviewed literature and clinical experience and acumen. Once implemented, trauma programs should **track compliance** with their clinical practice guidelines, protocols, and/or algorithms and ultimately monitor them for effects on outcome.

# Resources for Optimal Care of the Injured Patient

## Chapter 16 – PIPS

### Clinical Practice Guidelines, Protocols, and Algorithms

Examples of such activities include the following:

- ◆ The use of **massive transfusion protocols** in patients with exsanguinating hemorrhage.
- ◆ Assessment and clearance of the cervical spine.
- ◆ The management of **severe traumatic brain injury**.
- ◆ The reversal of oral anticoagulants, the timing of antibiotic administration, and time to the operating room for open fracture management.
- ◆ The use of **venous thromboembolism prophylaxis**.
- ◆ **Deep vein thrombosis or pulmonary embolism events.**



Original Investigation

# Association of Hospital Participation in a Surgical Outcomes Monitoring Program With Inpatient Complications and Mortality

David A. Etzioni, MD, MSHS; Nabil Wasif, MD, MPH; Amylou C. Dueck, PhD; Robert R. Cima, MD; Samuel F. Hohmann, PhD; James M. Naessens, ScD; Amit K. Mathur, MD, MS; Elizabeth B. Habermann, PhD, MPH

## Measuring Surgical Outcomes for Improvement Was Codman Wrong?

Donald M. Berwick, MD, MPP

“...Measurement alone is not enough for improvement. Weighing a pig does not make the pig fatter.”



# Collaborative Metrics



# MTQIP 2014 Collaborative Metrics

- ◆ Hemorrhage ( $\geq 4$  u PRBC's first 4 hrs)
  - % of patients with 4hr PRBC/FFP ratio  $< 2.5$ 
    - Begin = 34 %
    - Previous = 56 %
    - Current = **59 %**
    - Target = 80 %

# Patient List - Blood

recordno	traumactr	age	blunt	ed_arrrdate	ed_arrrtime	ed_bp	ed_pulse	ed_mtr	usrais_iss	prbc4	ffp4	plt4	cryo4	ratio4
						64	151	6	10	6	2	5	0	3
						110	81	1	38	10	10	10	0	1
						99	84	1	34	4	4	0	0	1
						137	100	1	22	4	0	0	0	
						107	106	6	16	7	8	15	0	0.875
						0	0	1	9	11	0	0	0	
						65	73	6	59	4	3	0	0	1.333333
						137	98	6	16	4	0	0	0	
						119	150	6	34	38	36	40	2	1.055556

- ◆ Your list of patients
- ◆ 0 = No
- ◆ 1 = Yes
- ◆ Injury, Blood products, TXA, Operation, Angio
- ◆ MTQIP Report Site (Hemorrhage)

# MTQIP 2014 Collaborative Metrics


## ◆ VTE

### ■ VTE Rate


- Begin = 2.5 %
- Previous = 1.4 %
- Current = **1.4 %**
- Target = 1.5 %

### ■ 48 hr VTE Prophylaxis Rate


- Begin = 38 %
- Previous = 40 %
- Current = **46 %**
- Target = 50 %




## Type VTE Prophylaxis



## Rate of VTE Prophylaxis by 48 hrs



## Rate of VTE Prophylaxis by 48 hrs





# MTQIP 2014 Collaborative Metrics

## ◆ Brain Injury

### ■ Selection Criteria


- AIS Head > 0, excluding vascular, scalp, and bony injuries
- Exclude if penetrating mechanism
- Exclude if no signs of life
- Exclude if direct admission transfer
- Exclude if Max GCS>8 and TBI GCS>8

# MTQIP 2014 Collaborative Metrics

## ◆ Brain Injury

- % of eligible patients with TBI intervention (Monitor or Operation)
  - Begin = 57 %
  - Previous = 70 %
  - Current = **72 %**
  - Target = 70 %

## TBI Mortality (Raw)



# Monitor or Operation for Head Injury (3/1/2013 to 9/30/14)

Inclusion:

Exclusion:

AIS Head > 0

Penetrating Mechanism


No signs of life

Direct Admit Transfer

Max GCS > 8 & TBI GCS > 8

<u>Trauma Cente</u>	<u>N</u>	<u>Dead</u>	<u>Alive w/o</u> <u>Intervent</u>	<u>Alive</u> <u>with</u> <u>Intervent</u>	<u>Dead w/o</u> <u>Intervent</u>	<u>Dead</u> <u>with</u> <u>Intervent</u>	<u>and</u> <u>Intervent</u> <u>Withheld</u>	<u>&amp; no</u> <u>Interve</u> <u>nt</u>	<u>Eligible</u>	<u>%</u> <u>Eligible</u> <u>w/no</u> <u>Interven</u>	<u>% Dead</u> <u>/ N</u>
21	78	39	17	22	20	19	16	4	45	9%	50%
27	59	18	25	16	10	8	0	10	34	29%	31%
19	46	21	16	9	12	9	7	5	23	22%	46%
4	46	15	15	16	10	5	9	1	22	5%	33%
3	39	23	8	8	10	13	4	6	27	22%	59%
18	36	18	6	12	10	8	7	3	23	13%	50%
10	33	14	11	8	11	3	0	11	22	50%	42%
1	32	12	10	10	7	5	0	7	22	32%	38%
11	32	19	4	9	13	6	3	10	25	40%	59%
17	28	11	12	5	5	6	1	4	15	27%	39%
20	25	9	8	8	6	3	2	4	15	27%	36%
13	23	10	9	4	6	4	3	3	11	27%	43%
23	22	10	11	1	7	3	3	4	8	50%	45%
5	20	11	5	4	9	2	3	6	12	50%	55%
6	19	12	4	3	7	5	0	7	15	47%	63%
12	18	13	3	2	10	3	5	5	10	50%	72%
14	18	8	9	1	7	1	1	6	8	75%	44%
15	18	9	2	7	7	2	4	3	12	25%	50%
22	16	6	3	7	3	3	0	3	13	23%	38%
7	16	15	1	0	10	5	9	1	6	17%	94%
8	14	8	4	2	4	4	2	2	8	25%	57%
9	13	7	2	4	7	0	6	1	5	20%	54%
26	11	5	3	3	1	4	0	1	8	13%	45%
24	10	3	5	2	2	1	0	2	5	40%	30%
16	10	7	1	2	2	5	2	0	7	0%	70%
2	8	7	0	1	4	3	2	2	6	33%	88%
25	5	5	0	0	4	1	0	4	5	80%	100%
Total	695	335	194	166	204	131	89	115	412	28%	48%

## TBI Intervention




# MTQIP 2014 Collaborative Metrics

## ◆ Brain Injury

- % of TBI intervention patients with timely intervention ( $\leq 8$  hrs after arrival)
  - Begin = 65 %
  - Previous = 68 %
  - Current = **80 %**
  - Target = 80 %

# TBI Intervention Timing

■ > 80% Timely  
■ < 80% Timely






# Patient List – TBI Intervention

any_m	brain_op	vent	ippm	o2mon	jvb	time_to_br	time_to_ve	time_to_ip	time_to_o2	time_to_jv	minimum_	earliest_pl	timely
1	0	1	0	0	0		700				11.66667	vent	0
1	0	1	1	0	0		944	944			15.73333	multiple	0
1	0	1	0	0	0		1696				28.26667	vent	0
1	0	0	1	0	0			1640			27.33333	ippm	0
1	0	1	1	0	0			402			6.7	ippm	1
0	0	0	0	0	0								0
0	0	0	0	0	0								0
1	0	1	0	0	0		278				4.63333	vent	1
0	0	0	0	0	0								0
0	0	0	0	0	0								0
1	1	1	0	0	0	410	410				6.83333	multiple	1
1	0	1	0	0	0		1248				20.8	vent	0

- ◆ Your list of patients
- ◆ 0 = No
- ◆ 1 = Yes
- ◆ MTQIP Report Site (TBI management & Timing of TBI interventions)



# MTQIP Outcomes

- ◆ ArborMetrix Report
- ◆ 3/1/2013 to 9/30/2014
- ◆ Rates
  - Risk and Reliability-adjusted
  - Red dash line is collaborative mean
- ◆ Legend
  -  Low-outlier status (better performance)
  -  Non-outlier status (average performance)
  -  High-outlier status (worse performance)

# MTQIP Shock - Angio

- ◆ 1/1/2013 to 9/30/2014
- ◆ Inclusion
  - First ED SBP or Lowest ED SBP  $\leq 90$  mmHg
  - Angio procedure
    - ◆ MTQIP hemorrhage data
    - ◆ Procedure data (ICD9 code)
- ◆ Exclude
  - Time to angio negative or  $> 24$  hrs

<u>Trauma Center</u>	<u>N Patients</u>	<u>Dead</u>	<u>Mean Time</u>	<u>Ratio</u>	<u>Ratio</u>	<u>Diagnostic</u>	<u>Therapeutic</u>
			<u>to Angio</u> <u>Procedure</u> <u>hrs</u>	<u>PRBC/FFP</u> <u>4 hrs</u>	<u>PRBC/FFP</u> <u>24 hrs</u>		
8	2	1	2.7	0.9	1.2	1	0
3	11	3	3.9	1.1	1.5	5	5
9	2	0	9.3	1	2	2	0
5	3	1	9.7	0.8	0.8	2	1
11	1	0	1.9	1.7	1.5	0	1
23	2	0	8.1	--	2.7	0	1
18	7	2	7.7	1.2	1.3	5	2
10	6	3	6.3	1.1	1.7	2	2
13	1	0	10.5	1	1	0	1
2	2	0	1.8	1.3	1.3	1	1
16	4	1	5.8	1.2	1.6	2	1
22	2	1	1.2	1.2	1.2	1	0
14	3	1	5.7	1.5	1.5	2	1
21	11	1	4.1	1.5	1.1	4	2
7	4	0	2.9	1.9	1.6	4	0
17	1	0	2.4	--	--	0	1
25	1	0	4.8	--	--	0	1
19	11	2	3.5	1.5	1.8	4	6
27	3	1	2.7	1.5	1.5	2	1
4	11	2	7.9	1.9	3	5	6
Total	88	19	5.2	--	--	42	33


<u>Trauma Center</u>	<u>N Patients</u>	<u>Diagnostic</u>	<u>Therapeutic</u>	<u>Liver</u>	<u>Spleen</u>	<u>Kidney</u>	<u>Pelvis</u>	<u>Retro</u>	<u>Neck or Extrem</u>	<u>Aorta</u>	<u>Other</u>
8	2	1	0	0	0	0	0	0	0	0	0
3	11	5	5	1	1	0	3	0	0	0	0
9	2	2	0	0	0	0	0	0	0	0	0
5	3	2	1	0	1	0	0	0	0	0	0
11	1	0	1	0	0	0	1	0	0	0	0
23	2	0	1	1	0	0	0	0	0	0	0
18	7	5	2	0	1	0	2	0	0	0	0
10	6	2	2	1	0	0	1	0	1	0	0
13	1	0	1	1	0	0	0	0	0	0	0
2	2	1	1	0	0	0	1	0	0	0	0
16	4	2	1	0	0	0	0	0	0	0	1
22	2	1	0	0	0	0	0	0	0	0	0
14	3	2	1	0	1	0	0	0	0	0	0
21	11	4	2	1	1	1	0	1	0	0	0
7	4	4	0	0	0	0	0	0	0	0	0
17	1	0	1	0	0	0	0	0	0	0	0
25	1	0	1	0	1	0	0	0	0	0	0
19	11	4	6	1	1	1	2	0	1	0	0
27	3	2	1	0	0	1	0	0	0	0	0
4	11	5	6	1	0	0	5	0	0	0	0
Total	88	42	33	7	7	3	15	1	2	0	1

# MTQIP Shock - Operation


- ◆ 1/1/2013 to 9/30/2014
- ◆ Inclusion
  - First ED SBP or Lowest ED SBP  $\leq$  90 mmHg
  - Operation
    - ◆ MTQIP hemorrhage data
- ◆ Exclude
  - Time to operation negative or  $>$  24 hrs

<u>Trauma Center</u>	<u>N</u> <u>Patients</u>	<u>Dead</u>	<u>Penetr</u> <u>ating</u>	<u>Mean</u> <u>Time to</u> <u>Operation</u> <u>hrs</u>	<u>Ratio</u> <u>PRBC/FFP</u> <u>4 hrs</u>	<u>Ratio</u> <u>PRBC/FFP</u> <u>24 hrs</u>	<u>Laparot</u> <u>omy</u>	<u>Thorac</u> <u>otomy</u>	<u>Sternot</u> <u>omy</u>	<u>Extremi</u> <u>ty</u>	<u>Neck</u>	<u>Amputat</u> <u>ion</u>
8	9	4	6	1.9	1.8	1.9	4	2	0	1	2	0
3	8	3	5	2.6	1.1	1.1	4	0	0	2	2	0
9	2	0	1	2.3	3.7	3.3	1	0	0	1	0	0
5	8	3	1	1.5	2.4	2.4	2	0	0	1	0	0
1	7	4	7	0.4	3.2	3.2	3	2	0	2	0	0
12	2	2	0	0.8	--	3	2	0	0	0	0	0
11	7	4	4	1.1	1.6	1.7	5	0	0	2	0	0
23	3	2	1	3.8	2	2	3	0	0	0	0	0
18	26	10	14	1.5	1.1	1.2	14	6	0	3	1	2
10	17	7	14	2.1	1.8	1.7	8	5	1	3	0	0
13	13	2	6	1.1	3.1	2.5	8	2	0	2	0	1
2	2	2	0	1.1	1.4	1.4	2	0	0	0	0	0
24	1	0	0	2.3	2.2	0.9	1	0	0	0	0	0
16	9	4	6	1.7	3.5	3.2	5	4	0	0	0	0
20	9	2	2	2.7	1.1	0.6	3	0	0	6	0	0
22	6	2	1	1.8	1.1	1.2	2	2	0	2	0	0
14	12	7	7	2.3	1.8	1.6	8	3	0	0	0	1
6	5	3	2	2.3	1.8	1.5	2	3	0	0	0	0
15	31	9	30	0.9	2.9	2.4	11	9	0	11	0	0
21	14	4	3	2.2	2.8	2.8	10	0	1	0	0	0
7	12	4	5	1.6	2.9	2.2	7	1	0	3	0	1
17	11	6	5	2.9	1.3	1.4	6	2	0	1	0	0
19	9	2	8	1.3	1.1	1.1	4	4	0	0	1	0
27	12	5	1	2.7	2	2.1	9	1	0	1	0	1
4	3	2	1	1.4	2.2	1.9	2	1	0	0	0	0
Total	238	93	130	1.8	--	--	126	47	2	41	6	6

## Mortality (Cohort 1 w/o DOA's)




## Mortality (Cohort 2 w/o DOA's)







## Mortality (Cohort 3 - Blunt Multi w/o DOA's)




## Case Volume Mortality (Cohort 3)



## Mortality (Cohort 4 - Blunt Single w/o DOA's)




## Mortality (Penetrating w/o DOA)




# Mortality (Cohort 6)


Admit to Non-Trauma Service



## Mortality (<65 yo)




## Mortality ( $\geq 65$ yo)



Trauma Center

# Mortality GCS 3-8






# TBI Mortality

## ◆ Brain Injury


### ■ Selection Criteria

- AIS Head > 0, excluding vascular, scalp, and bony injuries
- Exclude if penetrating mechanism
- Exclude if no signs of life
- Exclude if direct admission transfer
- Exclude if Max GCS>8 and TBI GCS>8


# Risk and Reliability Adjusted TBI Mortality




## Mortality or Hospice (Cohort 1 w/o DOA's)




**Mortality (Cohort 1 w/o DOA's)**




**Mortality or Hospice (Cohort 1 w/o DOA's)**




# DVT/Pulmonary Embolus




# Pneumonia



## Adjusted VAP




# Renal Failure







## C. Difficile Colitis




# Adjusted Ventilator Days




# Unplanned Intubation




# Patients Admitted to ICU




# Unplanned Return to ICU




# Adjusted ICU LOS



# Adjusted Hospital LOS



# Extended LOS





# **ARDS and Ventilators**

**Pauline Park, MD**





The Surgeon of the Future  
Innovation | Science | Moral Values  
CLINICAL CONGRESS 2014

# 2015 Faculty Disclosure Slide

LIPS-A - NIH/NHLBI U01HL108712

EPVENT2 - NIH/NHLBI UM1HL108724

PETAL - NIH/NHLBI U01HL123031

# ARDS Management: Overview 2015

➤ Low tidal volume ventilation  
Prone Positioning  
Early neuromuscular blockade

~~x HFOV~~  
~~iNO~~

? Transpulmonary pressure guided  
ventilator management  
ECMO

❖ Early intervention to reduce lung injury  
Long Term Outcomes  
Prevention in OR and ED



## The Lancet · Saturday 12 August 1967

### ACUTE RESPIRATORY DISTRESS IN ADULTS

DAVID G. ASHBAUGH  
M.D. Ohio State

ASSISTANT PROFESSOR OF SURGERY

D. BOYD BIGELOW  
M.D. Colorado

ASSISTANT IN MEDICINE AND AMERICAN THORACIC SOCIETY-NATIONAL  
TUBERCULOSIS ASSOCIATION FELLOW IN PULMONARY DISEASE

THOMAS L. PETTY  
M.D. Colorado


ASSISTANT PROFESSOR OF MEDICINE

BERNARD E. LEVINE  
M.D. Michigan

AMERICAN THORACIC SOCIETY-NATIONAL TUBERCULOSIS ASSOCIATION  
FELLOW IN PULMONARY DISEASE\*

*From the Departments of Surgery and Medicine,  
University of Colorado Medical Center, Denver, Colorado, U.S.A.*

**Summary** The respiratory-distress syndrome in 12 patients was manifested by acute onset of tachypnoea, hypoxaemia, and loss of compliance after a variety of stimuli; the syndrome did not respond to usual and ordinary methods of respiratory therapy. The clinical and pathological features closely resembled those seen in infants with respiratory distress and to conditions in congestive atelectasis and postperfusion lung. The theoretical relationship of this syndrome to alveolar



# Normal Ventilation (rat lung)




(courtesy Gary Nieman, SUNY Upstate)

# Injury (rat lung)



(courtesy Gary Nieman, SUNY Upstate)

# Despite therapy, some patients will develop refractory hypoxemia



# Acute Respiratory Distress Syndrome

## The Berlin Definition

ARDS Definition Task Force, JAMA 2012 Jun 20; 307 (23): 25-26

	Mild	Moderate	Severe
Timing	Acute within one week		
Hypoxia	300 – 201	$\leq 200$	$\leq 100$
PEEP	$\leq 5$	$\leq 5$	$\leq 10$
Radiology	Bilateral	Bilateral	> 3 quadrants
Vent			Ve > 10L CRS < 40



# Acute Respiratory Distress Syndrome

## The Berlin Definition

ARDS Definition Task Force, JAMA 2012 Jun 20; 307 (23): 25-26

	Mild	Moderate	Severe
Timing	Acute within one week		
Hypoxia	300 – 201	$\leq 200$	$\leq 100$
PEEP	$\leq 5$	$\leq 5$	$\leq 10$
Radiology	Bilateral	Bilateral	> 3 segments
Vent			
Anticipated			
Incidence	23%	63%	14%
Mortality	10%	32%	62%


In absence of known predisposing risk factor\* or not fully explained, assessment for cardiac failure required.

\*Pneumonia, aspiration, inhalation, pulmonary contusion, drowning  
sepsis, transfusion, trauma, pancreatitis, noncardiogenic shock, drug overdose

**Criteria for additional severity of disease did not enhance model and dropped from final definition**

# What do we actually think we know?


- Ventilation with high airway pressures is bad



**Figure 5.** Macroscopic aspect of rat lungs after mechanical ventilation at 45 cm H<sub>2</sub>O peak airway pressure. *Left:* normal lungs; *middle:* after 5 min of high airway pressure mechanical ventilation. Note the focal zones of atelectasis (in particular at the left lung apex); *right:* after 20 min, the lungs were markedly enlarged and congestive; edema fluid fills the tracheal cannula.

# What do we actually think we know?

- Lower tidal volume ventilation with pressure limitation is good
- Correction of hypoxia is not a good surrogate for mortality






## ➤ Standard of Care Lung Protective Ventilation

- 6ml/kg of predicted body weight
  - Males  $50 + 2.3 * (\text{height in inches above } 60'')$
  - Females  $45.5 + 2.3 * (\text{height in inches above } 60'')$
- Maintain Pplat < 30 with volume titration
- Permissive hypercapnia, treat acidosis with supplemental bicarbonate

# Treatment Strategies in ARDS





The Surgeon of the Future  
Innovation | Science | Moral Values  
CLINICAL CONGRESS 2014


# ➤ Prone Positioning



## Question 13 - Prone

How often do you use prone positioning in ARDS?


1. Never
2. Rarely (1-2x a year)
3. It's too much hassle
4. As part of routine care in patients with posterior atelectasis and severe hypoxia



Total: 118

# Q9: How often do you use prone positioning in ARDS?

Answered: 17 Skipped: 1








## ➤ Prone Positioning

- Previously, years of study, no clear impact
- Makes anatomic and physiologic sense
- Recent trial suggests mortality advantage early on in moderate to severe ARDS

# ARDS



Bilateral patchy opacities



- **“Baby Lung” Sitting on Top of a Consolidated Lung**
- **Posterior dependent lung consolidation**
- **Difficult to recruit**

# PROSEVA (Proning Patients with Severe ARDS)

## *The* NEW ENGLAND JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

JUNE 6, 2013

VOL. 368 NO. 23


### Prone Positioning in Severe Acute Respiratory Distress Syndrome

Claude Guérin, M.D., Ph.D., Jean Reignier, M.D., Ph.D., Jean-Christophe Richard, M.D., Ph.D., Pascal Beuret, M.D., Arnaud Gacouin, M.D., Thierry Boulain, M.D., Emmanuelle Mercier, M.D., Michel Badet, M.D., Alain Mercat, M.D., Ph.D., Olivier Baudin, M.D., Marc Clavel, M.D., Delphine Chatellier, M.D., Samir Jaber, M.D., Ph.D., Sylvène Rosselli, M.D., Jordi Mancebo, M.D., Ph.D., Michel Sirodot, M.D., Gilles Hilbert, M.D., Ph.D., Christian Bengler, M.D., Jack Richecoeur, M.D., Marc Gannier, M.D., Ph.D., Frédérique Bayle, M.D., Gael Bourdin, M.D., Véronique Leray, M.D., Raphaele Girard, M.D., Loredana Baboi, Ph.D., and Louis Ayzac, M.D.,  
for the PROSEVA Study Group\*

# PROSEVA - Study Overview

- Placing patients who require mechanical ventilation in the prone rather than the supine position improves oxygenation
- Enrolled Early Severe ARDS ( $P/F < 150$  mm Hg on  $FiO_2 \geq 0.6$ ,  $PEEP \geq 5$  cm  $H_2O$ , within 36 hours of onset)
- Prone 16 hours per day until improvement in supine position, mean 4.4 sessions per patient

# PROSEVA – Probability of Survival from Randomization to Day 90



## No. at Risk

Prone group	237	202	191	186	182
Supine group	229	163	150	139	136

**Table 3. Primary and Secondary Outcomes According to Study Group.\***

Outcome	Supine Group (N = 229)	Prone Group (N = 237)	Hazard Ratio or Odds Ratio with the Prone Position (95% CI)	P Value
Mortality — no. (% [95% CI])				
At day 28				
Not adjusted	75 (32.8 [26.4–38.6])	38 (16.0 [11.3–20.7])	0.39 (0.25–0.63)	<0.001
Adjusted for SOFA score†			0.42 (0.26–0.66)	<0.001
At day 90				
Not adjusted	94 (41.0 [34.6–47.4])	56 (23.6 [18.2–29.0])	0.44 (0.29–0.67)	<0.001
Adjusted for SOFA score†			0.48 (0.32–0.72)	<0.001
Successful extubation at day 90 — no./total no. (% [95% CI])	145/223 (65.0 [58.7–71.3])	186/231 (80.5 [75.4–85.6])	0.45 (0.29–0.70)	<0.001
Time to successful extubation, assessed at day 90 — days				
Survivors	19±21	17±16		0.87
Nonsurvivors	16±11	18±14		
Length of ICU stay, assessed at day 90 — days				
Survivors	26±27	24±22		0.05
Nonsurvivors	18±15	21±20		
Ventilation-free days				
At day 28	10±10	14±9		<0.001
At day 90	43±38	57±34		<0.001
Pneumothorax — no. (% [95% CI])	13 (5.7 [3.9–7.5])	15 (6.3 [4.9–7.7])	0.89 (0.39–2.02)	0.85
Noninvasive ventilation — no./ total no. (% [95% CI])				
At day 28	10/212 (4.7 [1.9–7.5])	4/228 (1.8 [0.1–3.5])	0.36 (0.07–3.50)	0.11
At day 90	3/206 (1.5 [0.2–3.2])	4/225 (1.8 [0.1–3.5])	1.22 (0.23–6.97)	1.00
Tracheotomy — no./total no. (% [95% CI])				
At day 28	12/229 (5.2 [2.3–8.1])	9/237 (3.8 [1.4–6.0])	0.71 (0.27–1.86)	0.37
At day 90	18/223 (8.1 [4.5–11.7])	15/235 (6.4 [3.3–9.5])	0.78 (0.36–1.67)	0.59

\* Plus-minus values are means ±SD. Hazard ratios are shown for mortality and successful extubation; odds ratios are shown for other outcomes. CI denotes confidence interval.

† There were no significant differences between the groups in organ dysfunction as assessed from the SOFA score (Table S4 in the Supplementary Appendix).

# PROSEVA

**C'est possible?  
Incredible effect size**

**- Day 28 and Day 90  
Adjusted and  
Unadjusted  
Mortality OR  
0.39 to 0.48  
with proning**

**- Majority of patients  
in both groups  
received  
neuromuscular  
blockade**

# PROSEVA - Conclusions

- In this trial, the investigators found a benefit with respect to all-cause mortality with this change in body position in patients with severe ARDS
- In patients with severe ARDS, early application of prolonged prone-positioning sessions significantly decreased 28-day and 90-day mortality



# UM SICU

## Demonstrates Prone Method

- 4 people
- 2 sheets
- Easy to do
- Easy to teach
- Quick
- Easy access to patient



**With flat sheet, pull patient to one side of the bed.**



**Tuck flat sheet around patient arm in order to protect it and move patient.**



**Place a second flat sheet on the bed, tuck under patient. Everything will pull through when you turn the patient.**



**Carefully turn the patient over and position prone by pulling the sheet. This will allow the arm and sheet to be pulled across the bed.**



**Discard the sheet that was pulled through, position lines and tubes.**



**Patient now prone. Place arms in swimmers position (one positioned up toward head, one at side. Place in Reverse Trendelenberg.**






The Surgeon of the Future  
Innovation | Science | Moral Values  
CLINICAL CONGRESS 2014

# ➤ Neuromuscular Blockade



## Question 8 - NMB


How often do you use neuromuscular blockade in initial treatment ARDS patients?



Total: 125

## Q6: How often do you use neuromuscular blockade in the initial treatment of ARDS patients?

Answered: 18 Skipped: 0






## ➤ Neuromuscular Blockade

- Frequently used to facilitate controlled ventilation
- Concerns regarding long term weakness and conflict with reduction in sedation protocols
- Recent trials suggest mortality advantage early on in moderate to severe ARDS


# ACURASYS – Study Overview

- The investigators induced muscle paralysis in patients with the acute respiratory distress syndrome (ARDS) by administering a neuromuscular blocking agent, cisatracurium besylate
- Continuous cisatracurium infusion for 48h in early ARDS(15mg bolus, 37.5mg per hour)
- RCT, 20 ICUs, 340 patients
- Moderate to severe ARDS ( $P/F < 150$ ), onset  $\leq 48$ h
- Lung protective ventilation

# ACURASYS – Enrollment



# ACURASYS - Probability of Survival through Day 90



# ACURASYS – Results

- Reduction in mortality from 40.7% to 31.6% (hazard ratio 0.68)
- Increased oxygenation, ventilator-free days and organ-failure free days
- No observed increases in functional weakness at day 28 or ICU discharge



# ACURASYS – Questions

- Underpowered
- No monitoring of neuromuscular blockade
- 40% received steroids for septic shock in both arms
- But same effect size as lung protective ventilation?

# ACURASYS -Conclusions

- As compared with placebo, cisatracurium resulted in a lower adjusted 90-day mortality without more severe sequelae of neuromuscular blockade
- In patients with severe ARDS, early administration of a neuromuscular blocking agent improved the adjusted 90-day survival and increased the time off the ventilator without increasing muscle weakness.



The Surgeon of the Future  
Innovation | Science | Moral Values  
CLINICAL CONGRESS 2014

# X High Frequency Oscillatory Ventilation




## Question 2 - HFOV

How often do you use high frequency oscillatory ventilation in ARDS?



# Q1: How often does your center use high frequency oscillatory ventilation (HFOV) in ARDS?

Answered: 18 Skipped: 0



## Question 4 - HFOV

What do you think will be the answer?


1. Earlier HFOV better
2. Earlier HFOV worse



Total: 115

# Q3: What do you think will be the answer?

Answered: 11   Skipped: 7







# X High Frequency Oscillatory Ventilation

- 2 large randomized trials failed to show benefit, possible harm
- Usage falling off like a rock



# Targeting Lung Recruitment






#### No. at Risk

HFOV	275	169	98	54	26
Control	273	181	92	54	39

OSCILLATE

# Subgroup – Baseline Hypoxemia






# X Inhaled vasodilators

- Cannot prove a mortality benefit in ARDS
- Still used in rescue, transport


**Q8: All of the following have been demonstrated as beneficial effects of inhaled nitric oxide in adult ARDS patients EXCEPT:**

Answered: 15   Skipped: 3



# Q7: How often do you use inhaled nitric oxide (NO) in ARDS?

Answered: 18 Skipped: 0






The Surgeon of the Future  
Innovation | Science | Moral Values  
CLINICAL CONGRESS 2014

# ? Transpulmonary Pressure-guided ventilator management (Pes)



## Question 5 - Ptp


How often do you use esophageal pressure monitoring and transpulmonary pressure guided ventilator titration in ARDS?





## Q4: How often do you use esophageal pressure monitoring and transpulmonary pressure guided ventilator titration in ARDS?


Answered: 18 Skipped: 0



## Question 7 - Ptp

What do you think will be the answer?


1. Transpulmonary pressure directed titration better
2. Transpulmonary pressure directed titration worse



Total: 94


# Q5: What do you think will be the answer?

Answered: 18 Skipped: 0





# Ptp - Esophageal balloon catheter




$P_{tp} \approx \text{airway pressure} - \text{esophageal pressure}$

# Mechanical Ventilation Guided by Esophageal Pressure in Acute Lung Injury

Daniel Talmor, M.D., M.P.H., Todd Sarge, M.D., Atul Malhotra, M.D., Carl R. O'Donnell, Sc.D., M.P.H., Ray Ritz, R.R.T., Alan Lisbon, M.D., Victor Novack, M.D., Ph.D., and Stephen H. Loring, M.D.

- Used esophageal balloon catheter to estimate transpulmonary pressure to guide PEEP settings
- 61 patients randomized
- Altered PEEP settings: down or to 5 cm H<sub>2</sub>O in 40%  
up 6 – 10 cmH<sub>2</sub>O in 40%
- Increased P/F ratio  
Mortality signal at 180 days
- Phase II trial funded and enrollment has begun

# HOLDS – END EXPIRATORY



Position cursor near end of the hold

## Question 5

A 56 year old man is admitted to the ICU with ARDS and sepsis 4 days after emergency colectomy and splenectomy following an MVC. His height is 65 inches; his weight is 285 pounds. On lung protective ventilator settings,  $\text{FiO}_2$  0.80, PEEP 15 cmH<sub>2</sub>O his:

Peak inspiratory pressure (PIP) is 35 cm H<sub>2</sub>O

Plateau pressure ( $P_{\text{plat}}$ ) is 30 cm H<sub>2</sub>O

End expiratory airway pressure ( $P_{\text{aw}}$ ) is 20 cm H<sub>2</sub>O

Esophageal balloon pressure ( $P_{\text{es}}$ ) is 17 cm H<sub>2</sub>O.

Transpulmonary pressure ( $P_{\text{tp}_{\text{exp}}}$ ) is estimated by the formula:

- A.  $P_{\text{es}} - \text{PEEP}$
- B.  $\text{PEEP} - P_{\text{es}}$
- C.  $P_{\text{plat}} - P_{\text{aw}}$
- D.  $P_{\text{aw}} - P_{\text{es}}$

## Question 5

A 56 year old man is admitted to the ICU with ARDS and sepsis 4 days after emergency colectomy and splenectomy following an MVC. His height is 65 inches; his weight is 285 pounds. On lung protective ventilator settings,  $\text{FiO}_2$  0.80, PEEP 15 cmH<sub>2</sub>O his:

Peak inspiratory pressure (PIP) is 35 cm H<sub>2</sub>O

Plateau pressure ( $P_{\text{plat}}$ ) is 30 cm H<sub>2</sub>O

End expiratory airway pressure ( $P_{\text{aw}}$ ) is 20 cm H<sub>2</sub>O

Esophageal balloon pressure ( $P_{\text{es}}$ ) is 17 cm H<sub>2</sub>O.

Transpulmonary pressure ( $P_{\text{tp}_{\text{exp}}}$ ) is estimated by the formula:

A.  $P_{\text{es}}$ -PEEP

B. PEEP- $P_{\text{es}}$

C.  $P_{\text{plat}}$ - $P_{\text{aw}}$

**D.  $P_{\text{aw}}$ - $P_{\text{es}}$**





Beth Israel Deaconess  
Medical Center



A teaching hospital of  
Harvard Medical School

# EPVENT II- PROTOCOL


A PHASE II PROSPECTIVE RANDOMIZED CONTROLLED  
TRIAL OF VENTILATION DIRECTED BY ESOPHAGEAL  
PRESSURE MEASUREMENTS.

WILL ENROLL 200 PATIENTS WITH MODERATE TO  
SEVERE ARDS BY THE BERLIN CONFERENCE  
DEFINITION IN SEVEN ACADEMIC MEDICAL CENTERS IN  
NORTH AMERICA

**BETH ISRAEL DEACONESS MEDICAL CENTER**  
**BOSTON, MA**

DANIEL TALMOR MD MPH, BIDMC

# VENTILATION PROTOCOLS- EPVENT GROUP



**Measure Ptpexp during an end-expiratory hold.**

**Increase (or decrease) PEEP to achieve  $P_{tpexp} = 0$**


- Incrementally changes according to the formula:  $[\text{new PEEP}] = [\text{initial PEEP}] - P_{tpexp}$

**Repeat this procedure until  $P_{tpexp} = 0$ .**

- If this formula dictates an increase in PEEP of more than 10 cmH<sub>2</sub>O, increase PEEP in increments of 10 cmH<sub>2</sub>O or less

**When  $P_{tpexp} = 0$ , reassess oxygenation**

# VENTILATION PROTOCOLS- CONTROL AND EPVENT GROUPS



The control group PEEP and tidal volume will be managed without reference to the esophageal pressure measurements.

FIO<sub>2</sub> and PEEP must be kept within one column of this table, moving right or left one column at a time as required.


Table 4- Oxygenation Management Table – Control Group

Step	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
F <sub>I</sub> O <sub>2</sub>	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.6	0.7	0.8	0.8	0.9	1.0	1.0
PEEP	5	8	10	10	12	14	16	18	18	20	20	20	20	22	22	22	24

Table 1- Oxygenation Management Table - EPVent group

Step	1	2	3	4	5	6	7	8	9	10	11	12	13
F <sub>I</sub> O <sub>2</sub>	0.3	0.4	0.5	0.5	0.6	0.6	0.7	0.7	0.8	0.8	0.9	0.9	1.0
P <sub>tp</sub> <sub>exp</sub>	0	0	0	2	2	3	3	4	4	5	5	6	6

# VENTILATION PROTOCOLS- CONTROL AND EPVENT GROUPS



**91 patients enrolled in US/Canada  
as of December, 2014**

**Table 4- Oxygenation Management Table – Control Group**

Step	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
$\text{FiO}_2$	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.6	0.7	0.8	0.8	0.9	1.0	1.0
PEEP	5	8	10	10	12	14	16	18	18	20	20	20	20	22	22	22	24

**Table 1- Oxygenation Management Table - EPVent group**

Step	1	2	3	4	5	6	7	8	9	10	11	12	13
$\text{F}_\text{I}\text{O}_2$	0.3	0.4	0.5	0.5	0.6	0.6	0.7	0.7	0.8	0.8	0.9	0.9	1.0
$\text{Ptp}_\text{exp}$	0	0	0	2	2	3	3	4	4	5	5	6	6



The Surgeon of the Future  
Innovation | Science | Moral Values  
CLINICAL CONGRESS 2014


# ? Extracorporeal Membrane Oxygenation (ECMO)



## Question 15 - ECMO

How often do you use or refer for ECMO in ARDS?


1. Never
2. Rarely (1-2x a year)
3. Are you kidding?
4. As part of algorithm for care in patients with severe ARDS



Total: 123

# Q11: How often do you use or refer for extracorporeal membrane oxygenation (ECMO) in ARDS?

Answered: 18 Skipped: 0



## Question 16 - ECMO

Which of the following is true regarding ECMO in adult patients with ARDS?

1. VA-ECMO is associated with decreased mortality compared to VV-ECMO
2. Anticoagulation is required but is not associated with increased complications
- 3. Transfer to a specialized center with ECMO capabilities is associated with decreased mortality**
4. ECMO is contraindicated after  $\geq 5$  days of mechanical ventilation




Answer: 3

Total: 92



## Q12: Which of the following is true regarding ECMO in adult patients with ARDS?

Answered: 15 Skipped: 3






# ? Extracorporeal Membrane Oxygenation (ECMO)

- Resurgent interest with more compact systems, favorable results in influenza H1N1
- Continuous life support, resource and labor-intensive, conclusive trials controversial
- Some evidence for regionalization


# Bartlett





First successful ECLS Patient; ARDS/ trauma  
Santa Barbara, Ca, 1971.

J Donald Hill MD and Maury Bramson BME




RHB

## Veno-venous ECLS with a double lumen cannula



48/0 LEFT



# Afghanistan to Regensburg ECMO transport



PHOTO BY SETH ROBBINS/Stars and Stripes

Dr. Matthias Amann, left, and Dr. Alois Philipp make preparations to transport a 22-year-old soldier to the university hospital in Regensburg, Germany. Philipp helped develop the ECMO machine that was used on the wounded soldier during an evacuation.

## Lifesaving INNOVATION

Portable heart-lung machine used in combat evacuation

BY SETH ROBBINS  
Stars and Stripes

**A** LANDSTUHL, Germany  
U.S. team for the first time in a  
combat evacuation has used an in-  
novative and portable heart-lung  
machine, saving a 22-year-old soldier  
wounded in Afghanistan.

the most serious lung injuries and evacuate  
them to Germany.

Within hours, Wanek and her team were  
bound for Kandahar.

When they got there Wednesday, they op-  
erated on him for five hours and tried several  
different ventilators, but all of them failed.

"I just could not improve his oxygenation  
to the point where it was safe," Dr. Wanek



The ECMO machine

STARS  AND STRIPES<sup>®</sup>

October, 2010



# Severe Thoracic Trauma


- Transmediastinal Gunshot Wound
- Combat Casualty
- Damage Control Thoracic Surgery
- Hilar Clamp for initial control





- Right pneumonectomy
- Severe ARDS
- ECMO Support initiated at a Level III Hospital in Afghanistan
- Continued by ALRT in-flight to Landstuhl Germany





Complete recovery, empyema complication



Conventional Ventilation or  
ECMO for  
Severe  
Adult  
Respiratory Failure




Kaplan-Meier survival estimates, by allocation

**31% Mortality reduction in Specialized Center**

**ECMO 63% (57/90) survived to 6 months without disability vs. 47% (41/87)**

**Relative risk (death or severe disability), 0.69; 95% CI 0.05 – 0.97;  $P = .03$ ; RR death 0.73; 95% CI 0.52-1.03**




**Table 2.** Deaths Analyzed by Matching Methods


Matching method	No. of Deaths/ Total No. of Patients (%)		RR (95% CI)	P Value
	ECMO-Referred	Non-ECMO-Referred		
Propensity score	18/75 (24.0)	35/75 (46.7)	0.51 (0.31-0.84)	.008
GenMatch	18/75 (24.0)	38/75 (50.7)	0.47 (0.31-0.72)	.001
Individual	14/59 (23.7)	31/59 (52.5)	0.45 (0.26-0.79)	.006

Abbreviations: ECMO, extracorporeal membrane oxygenation; RR, relative risk.

**80 referred for ECMO; 69 received (86.3%); hospital mortality 27.5%**



No. at risk										
ECMO-referred patients	59	54	51	50	49	48	47	46	46	46
Non-ECMO-referred patients	59	36	32	32	29	29	29	29	29	29



No. at risk										
ECMO-referred patients	75	69	66	64	62	61	59	58	58	58
Non-ECMO-referred patients	75	47	47	46	44	44	43	43	43	43

*Noah MA, et al. JAMA 2011;306(15):1659-1668.*


# Extracorporeal Membrane Oxygenation for Pandemic Influenza A(H1N1)-induced Acute Respiratory Distress Syndrome

## A Cohort Study and Propensity-matched Analysis


Tài Pham<sup>1,2</sup>, Alain Combes<sup>3,4</sup>, Hadrien Rozé<sup>5</sup>, Sylvie Chevret<sup>2,6</sup>, Alain Mercat<sup>7,8</sup>, Antoine Roch<sup>9,10</sup>, Bruno Mourvillier<sup>11,12</sup>, Claire Ara-Somohano<sup>13,14</sup>, Olivier Bastien<sup>15,16</sup>, Elie Zogheib<sup>17</sup>, Marc Clavel<sup>18,19</sup>, Adrien Constan<sup>1</sup>, Jean-Christophe Marie Richard<sup>20,21,22</sup>, Christian Brun-Buisson<sup>1,23,24</sup>, and Laurent Brochard<sup>20,21,24</sup>; for the REVA Research Network\*

**Matched 52/123 pts receiving ECMO; mortality varies with replacement**

REVA main analysis  
(matched sample without replacement)



REVA matched sample with replacement



# EOLIA ECMO Trial

- ECMO to rescue Lung Injury in severe AARDS

- Multicenter ECMO trial

- Enrolling in France, Australia, US
- 157 patients as of January, 2015

- Control cohort with modern ARDS ventilator management, and rescue strategies allowed

- Inclusion criteria
1. Severe ARDS defined according to usual criteria, and
  2. Meeting 1 of the 3 following criteria of severity:
    - a.  $\text{PaO}_2/\text{FiO}_2$  ratio  $<50$  mm Hg with  $\text{FiO}_2 \geq 80\%$  for  $>3$  hours, despite optimization of mechanical ventilation and despite possible recourse to usual adjunctive therapies (NO, recruitment maneuvers, prone position, HFO ventilation, almitrine infusion) OR
    - b.  $\text{PaO}_2/\text{FiO}_2$  ratio  $<80$  mm Hg with  $\text{FiO}_2 \geq 80\%$  for  $>6$  hours, despite optimization of mechanical ventilation and despite possible recourse to usual adjunctive therapies (NO, recruitment maneuvers, prone position, HFO ventilation, almitrine infusion) OR
    - c.  $\text{pH} < 7.25$  for  $>6$  hours (RR increased to 35 /min) resulting from MV settings adjusted to keep  $\text{Pplat} \leq 32$  cm H<sub>2</sub>O (first,  $\text{Vt}$  reduction by steps of 1 mL/kg to 4 mL/kg then PEEP reduction to a minimum of 8 cm H<sub>2</sub>O)
  3. Obtain patient's consent or emergency consent

Randomization

for  $>6$  hours, despite mandatory use of recruitment maneuvers, and inhaled NO/prostacyclin and if technically possible a test of prone position.

Judgement criteria

Primary endpoint: all-cause mortality at D60

Secondary outcomes:

- Mortality at D30 and D90, in the ICU and in-hospital
- Number of days, between inclusion and D60, alive without mechanical ventilation, without hemodynamic support and without organ failure
- Number of patients developing pneumothorax between D1 and D60
- Number of infectious, neurological and hemorrhagic complications
- Duration of mechanical ventilation, and ICU and hospital stays




## ❖ Long Term Outcomes

- Increased awareness of critical care myopathy, persistent inflammation, immunosuppression and catabolism syndrome
- Just discharging the patient from the ICU is not sufficient any more




# A “Genomic Storm” induced by severe blunt trauma

## A. Effect of Severe Blunt injury on Probe Expression




## B. Up-regulated Pathways


Integrin signaling  
Leukocyte extravasation  
Fcγ Receptor mediated phagocytosis  
IL-10 signaling  
Toll-like receptor signaling  
Ephrin Receptor signaling  
IL-6 signaling  
TREM1 signaling  
Actin Cytoskeleton signaling  
B cell receptor signaling




## C. Down-regulated Pathways

Ca<sup>2+</sup> T cell apoptosis  
iCOS-iCOSL signaling in T cells  
CTLA4 signaling in CD8 T cells  
CD28 signaling in T cells  
T cell receptor signaling  
CD8 T cell mediated apoptosis  
Role of NFAT in immune response  
IL-4 signaling  
Primary immunodeficiency signaling  
Purine Metabolism







# The Big Hit



# The Slow Burn



# Relapsing Recurrences





# *The* NEW ENGLAND JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

APRIL 7, 2011

VOL. 364 NO. 14

## Functional Disability 5 Years after Acute Respiratory Distress Syndrome



- ARDS survivors had substantial recovery at one year, but persistent deficits at 5 years for exercise tolerance, quality of life



The Surgeon of the Future  
Innovation | Science | Moral Values  
CLINICAL CONGRESS 2014

❖ Focus on early intervention to prevent or reduce the severity of acute lung injury



# Need to Transform Medical Research in the 21st Century

## 20<sup>th</sup> Century

- **Treat disease when symptoms appear and normal function is lost**

- **Did not understand the molecular and cellular events that lead to disease**

- **Expensive in financial and disability costs**

## 21<sup>st</sup> Century


- **Intervene before symptoms appear and preserve normal function for as long as possible**

- **Understanding preclinical molecular events and ability to detect patients at risk**


- **Orders of magnitude more effective**



# The Future Paradigm: Preempt Disease



# “Chaos” of Critical Illness





The Surgeon of the Future  
Innovation | Science | Moral Values  
CLINICAL CONGRESS 2014

# ❖ Prevention

- Never as exciting.....
- But \*always\* makes more sense

# Prevention and Personalized Medicine for ARDS

## The New England Journal of Medicine

© Copyright, 2000, by the Massachusetts Medical Society

VOLUME 342

MAY 4, 2000

NUMBER 18




VENTILATION WITH LOWER TIDAL VOLUMES AS COMPARED WITH  
TRADITIONAL TIDAL VOLUMES FOR ACUTE LUNG INJURY  
AND THE ACUTE RESPIRATORY DISTRESS SYNDROME


THE ACUTE RESPIRATORY DISTRESS SYNDROME NETWORK\*



•Will earlier alterations in  
ventilation *prevent* ARDS?  
Gajic and colleagues



•Can ventilation settings be  
*personalized*?  
Marini and others




# **Lung Injury Prevention Study with Aspirin**

***LIPS-A Kick-off Meeting***


NIH, Bethesda, MD

Nov. 8, 2011






# LIPS-A Study Schematic










# Platelets and platelet-neutrophil interactions in sepsis and ALI

## A Platelets in Sepsis



## B Platelets in ALI and ARDS





# Platelets and platelet-neutrophil interactions in sepsis and ALI

## A Platelets in Sepsis

Circulating Platelet

Activated Platelet



Platelet Aggregate

## B Platelets in ALI and ARDS

Platelet-Activating Factor  
Beta-thromboglobulin  
Thrombospondin  
Thromboxane A<sub>2</sub>

Activated Platelets & Platelet Aggregates


**400 patients enrolled as of November, 2014, in analysis**






- 12 Clinical Centers, 1 Coordinating Center (Michigan Center – UMich and Henry Ford)
- Focus on trials of prevention and early intervention in lung injury
- Multidisciplinary focus: Pulmonary, ED, Surgery to address continuum of care


# Treatment paradigm in ARDS




# Treatment paradigm in ARDS



# Treatment paradigm in ARDS



# Treatment paradigm in ARDS





The Surgeon of the Future  
Innovation | Science | Moral Values  
CLINICAL CONGRESS 2014

parkpk@umich.edu

**Pauline K. Park MD, FACS, FCCM**  
University of Michigan School of Medicine  
Ann Arbor, MI



AMERICAN COLLEGE OF SURGEONS  
*Inspiring Quality:  
Highest Standards, Better Outcomes*

100+ years

AMERICAN COLLEGE OF SURGEONS | DIVISION OF EDUCATION  
*Blended Surgical Education and Training for Life*

**Lunch**



# **Site Specific PI Reports Under and Over Triage**

**Judy Mikhail, MSN MBA**





# Under and Over Triage

**Figure 2** The Matrix Method for the Calculation of Triage Rates

	Not Major Trauma	Major Trauma	Total	Overtriage
Highest Level TTA	A	B	C	$A/C \times 100$
Midlevel TTA	D	E	F	Undertriage =
No TTA	G	H	I	$(E+H) / (F+I) \times 100$

# Under and Over Triage

- ◆ William Beaumont Hospital
  - Holly Bair, MSN, NP
  - Randy Janczyk, MD
- ◆ Borgess Hospital
  - Mican Deboer, MSN
  - Tom Rohs, MD
- ◆ Bronson Methodist Hospital
  - Rita Cox, BSN
  - Scott Davidson, MD

# The Topic

**Beaumont Health System**

**Randy Janczyk, MD**

**Holly Bair, MSN, NP**

# The Problem/The Barriers

- Triage system based on mechanism of injury as well as physiologic criteria
- Trauma volume, Level I & Level II activations, have increased every year → appropriate mobilization of resources by mobilizing full trauma team only when needed
- Level II activations admitted to higher level care areas (i.e. ICU) → question of under triage?
- ACSCOT visits 2011 and 2014 identified under triage as a weakness

# **Actions Taken**

- **Reviewed all trauma patients admitted to Trauma Service**
- **Evaluated using Beaumont Health Level I & Level II activation guidelines for appropriateness of activation**
- **Reviewed in Trauma PI all under triage charts**
- **Reviewed activation guidelines with EC staff and charge RN**


# Outcomes (Results)

- Acceptable rate per ACSCOT guidelines of 5% under triage rate
- Under triage rate at 11% initially
- Rate decreased to 4% - 3% - 3% for the three quarters of the audit

# Sustaining The Change

- Continued review of guidelines
- Review cases of under and over triage at Trauma QI
- Share results with Emergency Center and Trauma Service staff

# Future Directions



**Continue to Monitor Under Triage Rates**





# Review of MTQIP Site Project 2014

## Elderly Ground Level Falls

Thomas Rohs, Jr., MD and Mican DeBoer BSN, RN, CEN

**BORGESS**

# Problem

- Undertriage of elderly patients presenting with ground-level fall (GLF) as the MOI
- **Performance indicator:** Patients  $\geq 65$  years with ISS  $\geq 15$  that were not a Tier I or Tier II trauma activation
- **Baseline data:**
  - April-Sept, 2014, 21 patients undertriaged
  - 11/21 GLF
  - 8/11 had isolated head injuries, all over 80 YO
  - None of these pts met activation criteria


# Actions Taken

- Introduced proposal to modify Tier II activations to include pts  $\geq 65$  on anticoags/antiplatelets who have GLF
- Partnered with ED and inpatient services admission group to increase buy-in to involve trauma early
- Case reviews/presentations on geriatric trauma: WMAC annual conference, EMS con't ed event; Regional Emergency Summit

# Outcomes

- Trauma physician group turned down proposal to include GLF in Tier II activation criteria
- Instead, TMD worked with ED medical director to build pathway to expedite these patients through the system
- Currently in the education phase

## Geriatric (≥65) Ground Level Fall/Head Trauma Pathway



**Goals of care:** <sup>1</sup> ED MD eval ≤20 min after arrival

<sup>2</sup> CT ≤30 min

<sup>3</sup> Trauma eval and product/med administration ≤60 min

# Implementing/Sustaining Change

- Education among ED providers and nurses
- Tracking performance indicators through registry
- Reporting compliance at monthly multidisciplinary trauma peer review meetings
- Reporting at monthly ED quality meetings
- Modify pathway as necessary to meet needs of this population

# Future Directions

- Measure compliance with meeting performance indicators instead of relying on Cribbari matrix to calculate undertriage rates

# Questions







# **TRAUMA OVER/UNDER TRIAGE**

## **2014 MTQIP Performance Improvement Project**

**Bronson Methodist Hospital**

Scott Davidson, MD, FACS

Rita Cox, BSN, RN



# Problem/Barriers

- Orange book suggests acceptable undertriage rate of 5% or less
- Orange book suggests acceptable overtriage rate 25-35%
- Identified BMH rates higher than acceptable range




# Actions Taken

- Goal: To improve trauma triage rates through education and promotion of adherence to trauma team activation criteria
- Monthly tracking on Trauma Scorecard
- Chart reviews
- MTQIP PI Project



# Outcomes





# Process

- Daily review for over/under triage
- Once issue identified, referred to ED Liaison for review
- ED Liaison reviews with provider
- Case discussed at Peer Review and summarized for PIPS committee
- Monitored on Trauma Scorecard



# Process

Registry NoLast Name First Name

TRAUMA TEAM ACTIVATION

17:15

Adult/Peds Activation Activation Level Activation Date Activation Time Appropriate Level

ADULT I 16:55 APPROP

TFS H&P Sign-In? Backboard Removal Time

C C C 17:48

☐ Backboard > 40 mins.

☐ Approp.Pre-hospital & ED Triage

☐ Absent Hourly Charting

☐ ED LOS > 2 hrs.

Criteria
GCS <14

Location Date Source Code Description Event

PREHOSP 11/02/2014 TPI ACS992 APPROPRIATENESS OF PREHOSP

PR Date PR Judgement System Related Disease Related Provider Related Provider Status

11/03/2014

Further explanation /comments

Action Refer to/responsible Loop Closure

Peer Review

TPM Review / / TPI Review 11/11/2014 TMD Review / / Other Reviewer / /

First Previous New Next Last



# Sustaining the Change

- Continue to monitor through PI process
- Partnering with Emergency Medicine and Prehospital providers
- Chart reviews



# Future Directions

- Protocol development to decrease undertriage
- Monitor through PIPS
- Fallout review with EM Liaison





**Thank you!**  
[bronsonhealth.com](http://bronsonhealth.com)

# **Learning from peer collaboratives Michigan Urology Surgery Improvement Collaborative (MUSIC)**

**James Montie, MD  
Susan Linsell, MHSA**





# **Michigan Urological Surgery Improvement Collaborative**

## **Making Michigan #1 in Prostate Cancer Care**

**Jim Montie, MD  
Susan Linsell, MHSA**

**February 10, 2015**




# Vital statistics

## ● MUSIC Participants:

- 42 practices
- 235 urologists (~90% of urologists in state)
- 4 patient advocates

## ● Data Collection:

- 36 practices
- More than 15,000 cases in the registry
  - > 13,500 biopsies and 2,800 radical prostatectomies





# Current QI Activities

1. **Appropriate imaging**
1. **Safer prostate biopsy**
2. **Improve radical prostatectomy perioperative and functional outcomes**
3. **Appropriate treatment**




# 1. Appropriate Imaging

**Rationale: Focus of AUA  
Choosing Wisely Campaign**



# Imaging





# Imaging

- MUSIC data demonstrated a + Bone Scan or CT Scan for intermediate risk patients was *rare* (<1%)
- Developed imaging *appropriateness criteria* based on literature review, guidelines, and MUSIC data with collaborators from UM Industrial Engineering





# MUSIC Imaging Appropriateness Criteria

- Order a Bone Scan if:
  - » Gleason Score  $\geq 8$
  - or
  - » PSA  $>20$
- Order a CT Scan if:
  - » Gleason Score  $\geq 8$
  - or
  - » PSA  $>20$
  - or
  - » Clinical T Stage  $\geq T3$

**“Do when you should,  
don’t when you shouldn’t”**



# MUSIC Imaging Appropriateness Criteria

## Imaging Goals

**Perform Imaging in  
 $\geq 95\%$  of patients  
meeting criteria**


**Perform imaging in  
 $< 10\%$  of patients  
NOT meeting criteria**

**“Do when you should,  
don’t when you shouldn’t”**




# Imaging Appropriateness: Collaborative Wide


## % BS When Shouldn't




## % CT When Shouldn't



## % BS When Should



## % CT When Should






## **2. Making Prostate Biopsy Safer**

**Rationale: Increasing sepsis rate nationally to 2-4 % of biopsies**



# Reducing prostate biopsy-related hospitalizations

- Baseline prostate biopsy-related hospitalization rate of 1.26%
- 92% of hospitalizations due to infection
- 79% of cultures identified a fluoroquinolone resistant organism



The challenge is addressing fluoroquinolone resistance



# Pathways for addressing Fluoroquinolone resistance

## Culture-Specific Antibiotics (Rectal Swab Culture) \* (See IV for High-Risk patients)


<i>Culture Sensitive to Ciprofloxacin:</i>	<i>Culture Resistant to Ciprofloxacin but sensitive to TMP/SMX or Cephalosporins:</i>	<i>Culture Resistant to Ciprofloxacin, Cephalosporins, TMP/SMX:</i>
Ciprofloxacin PO	Culture directed antibiotics: (e.g., TMP/SMX PO, Cefazolin IM, Ceftriaxone IM)	Gentamicin IM + / – Clindamycin IM

## Augmented Antibiotics (No Culture Available)

<i>Antimicrobial of Choice:</i>	<i>Alternate Antimicrobials:</i>	<i>Allergic to Penicillins, Fluoroquinolones, and Cephalosporins:</i>
Fluoroquinolone (Cipro) PO + Gentamicin IM	Fluoroquinolone (Cipro) PO + Cefazolin IM  or Alternative based on local antibiogram (e.g., Cefuroxime, Zosyn)	Gentamicin IM + / – Clindamycin IM



# Collaborative-wide hospitalization rates





### **3. Improving perioperative and functional outcomes after radical prostatectomy**

**Rationale: Morbidity of RP major driver in early detection debate**






# Post Prostatectomy Perioperative Care

- At Jan 2014 MUSIC meeting, we presented data that showed our initial method of tracking complications was not reliable or actionable
- Thus, on March 20, 2014, we changed to tracking how cases followed an *“uncomplicated”* pathway of post-op recovery



# MUSIC-Notable Outcomes and Trackable Events after Surgery (NOTES)


## Uncomplicated Recovery Pathway



This pathway allows us to collect objective data that can show a surgeon how perioperative care varies and represents unanticipated events (complication) that can negatively impact patient short-term recovery



# Overall Case Deviation (at least one deviation)



# NOTES report




## MUSIC NOTES

NOTABLE OUTCOMES and TRACKABLE EVENTS after SURGERY

Surgeon #####

Data from 4/1/2014 to 6/30/2014

### Uncomplicated Recovery Pathway



#### Cases Deviated from Pathway:





Surgeon ##### 2.9%

Practice ### 33.3%

Full Collaborative\* 19.8%

\* excluding this practice  
**Bold Red** indicates values significantly worse than Collaborative  
**Bold Green** indicates values significantly better than Collaborative

Deviations from Pathway	Percentage Deviated Cases		
	Surgeon (n=35)	Practice (n=69)	Collaborative (n=2093)
Rectal Injury	0.0%	0.0%	0.1%
EBL > 400mL	<b>0.0%</b>	18.2%	11.3%
LOS > 2 days	2.9%	<b>29.0%</b>	9.6%
Drain Placement > 2 days	0.0%	<b>36.8%</b>	11.6%
Catheter Placement > 16 days	0.0%	10.0%	5.0%
30-day Readmission	0.0%	0.0%	1.2%
30-day Mortality	0.0%	0.0%	0.1%



BLUE represents this Surgeon's data - GREEN represents this Practice's data - BLACK represents the Collaborative-wide data (excluding this practice)



# MUSIC Patient Reported Outcomes: so far...


	MUSIC Goals	Baseline	3 month	6 month
Patients Enrolled	99%	86%	97%	100%
Questionnaire Completed	75%	94%	89%	97%
Paper Questionnaires	<20%	31%	29%	30%
Patient Requiring Phone Calls	TBD	24%	20%	9%

**Table Legend:** ●: >10% of MUSIC Goals    ●: <10% of MUSIC Goals    ●: Goal Met



# Patient Reported Outcomes: Trend Report

<b>JOHN DOE</b>		<b>Prostatectomy</b>
<b>DOB: 01/01/1901</b>	<b>Today's Date: 12/10/2013</b>	<b>Surgery date: 08/05/2010</b>
<b>Demographic, Lab and Pathology Data</b>		
<b>Age: 66</b>	<b>Months since surgery: 30</b>	
<b>Current PSA: &lt;.01</b>	<b>Current PSA date: 07/10/2010</b>	<b>Pre-op PSA: 5.5 ng/ml</b>
<b>Pathology Stage: T2b N0 M0</b>	<b>Pathology Gleason Score: 3 + 4</b>	<b>Margin status: Negative</b>
<b>Survey Data</b>		
<b>Survey completed:</b> 01/15/2013	<b>Quality of Life (current): 8/10</b>	<b>Bowel Function:</b> No bowel symptoms
<b>Erectile Function</b>		
<b>Baseline: 24/30</b>	<b>Current: 18/30</b>	<b>Current Erectile Aids Used:</b> Viagra—use it sometimes
<b>Urinary Function</b>		
<b>Baseline: 21/21</b>	<b>Current: 21/21</b>	<b>Current Pad Use:</b> None





# The opportunity in Michigan: 12 case pilot video review assessment

**Video Review List // Video Review**

Review ID: 6, Procedure: Bladder Neck, Review Type: Radical Prostatectomy, Status: Open, Number of Reviews Completed: 2

**GEARS REVIEW**  
Please rate, where 1 is poor and 5 is good

DEPTH PERCEPTION \* 1 2 3 4 5

BIMANUAL DEXTERITY \* 1 2 3 4 5

EFFICIENCY \* 1 2 3 4 5

FORCE SENSITIVITY \* 1 2 3 4 5

AUTONOMY \* 1 2 3 4 5

ROBOTIC CONTROL \* 1 2 3 4 5

OVERALL RESULTS \*

COMMENTS

- Is video assessment by peers or “crowd” feasible?---YES
- Are measurable differences evident between surgeons?---YES
- Does technique/skill correlate with outcomes?---?
- Can coaching improve performance?---?



## **4. Appropriate Treatment**

**Rationale: great concern regarding overtreatment**





# Active Surveillance: favorable practice patterns in Michigan





Fig. 3 – Adjusted likelihood of active surveillance for men with low-risk prostate cancer, stratified by Michigan Urological Surgery Improvement Collaborative practices. Model adjusts for age, Charlson Comorbidity Index score, number of positive cores, and primary payer. CI = confidence interval.



# Variation and Appropriate Treatment


- Variation is appropriate when it can be explained by factors that are considered relevant in treatment decisions



Variation is *inappropriate* when explained by insurance status, ethnicity, ancillary profit, etc.



# Treatment and Life Expectancy





# **MUSIC development of Appropriate Use Criteria**

- **Well-developed RAND/UCLA Method**
- **Panel of physicians create a series of detailed clinical scenarios based on a list of parameters**
- **A defined process is used to score specific clinical scenarios as “Appropriate”, “Uncertain”, “Inappropriate”**
- **The measures must recognize that patient preferences will trump the criteria in some cases**



# Demonstrating the Value of MUSIC




# Participant Engagement

- **Recruitment trips and site visits**
- **Regular provider interaction through emails and phone calls**
- **Commitment to excellent customer service**
- **Working groups (3 – 6 members) focused on each QI priority**
- **Health Policy/Administrative Benefits:**
  - » **PQRS Qualified Clinical Data Registry**
  - » **CME**



# Value to clinicians

**How likely would you be to recommend MUSIC to other urologists who are not members of the collaborative?**





# Value expressed by a MUSIC patient advocate

*"I just wanted to give you my two cents worth about the subject conference call. My thought is that a video is an excellent way for all to improve. An individual may be doing something a specific way and may not realize that a minor change could have a significant impact on the result. It is a great challenge and a very noble effort to make outcomes for patients better.*

*Thanks for having me part of this interesting process."*





# Shameless Promotion of MUSIC

*“Perhaps equally important to the data collected are the model and methods themselves. It is remarkable that the MUSIC voluntary effort includes nearly 90 per cent of the urologists in Michigan. This type of clear headed and proactive cooperative thinking and pooling of data which combines best patient guidelines/recommendations with health system financial considerations for medical practice patterns should serve as a model for emulation across the whole span of clinical practice issues.”*

Sagalowsky (UTSW), Editorial in *Urology*



# “Value” framework

$$*Value = Appropriateness \left( \frac{Outcomes}{Cost} \right)$$

Appropriateness = appropriateness score + patient preference

Outcomes = peri-op score + PRO score + cancer control

**For the first time, I think we can actually tackle *value* because we can quantify appropriateness, outcomes, and cost**

\*Adapted from D. Spahlinger



# Thank you



# **Program Manager Updates**

**Judy Mikhail, MSN MBA**



# MTQIP Program Manager Update 2/10/15

Judy Mikhail, MSN, MBA, RN

1. 2015 Site Specific Projects
2. 2016 Performance Index
3. Taxonomy Opportunity

# 2015 MTQIP Site Specific Topics

Complications	Utilization	Practices
<ul style="list-style-type: none"> <li>• Single complication</li> <li>• Number of Complications: 1,2,3,4,5+</li> <li>• Grade of Complications: I, II, III</li> <li>• Serious complications</li> <li>• Any complications</li> </ul>	<ul style="list-style-type: none"> <li>• Hospital LOS</li> <li>• Extended LOS</li> <li>• ICU LOS</li> <li>• Patients admitted to ICU</li> <li>• Unplanned intubation</li> <li>• Unplanned return to OR</li> <li>• Unplanned return to ICU</li> </ul>	<ul style="list-style-type: none"> <li>• VTE prophylaxis type</li> <li>• IVC filter use</li> <li>• Ventilator days</li> <li>• Patients on ventilator</li> <li>• ICP monitor use</li> <li>• ICP monitor timing</li> </ul>

## **Data Source:**

- MTQIP Reporting Website
- Paper reports at meetings

## **Deadlines:**

- Revolve around MTQIP mtg dates
- Cycle runs Feb 2015 to Feb 2016
- Many projects may take 2 years to “move the needle”

## **Dates:** (up to 7 days post MTQIP meeting)

- 1) Baseline: 2/10-2/17
- 2) Progress: 5/13-5/20
- 3) Progress: 10/13-10/20
- 4) Yr End Final: 2/10/-2/17 2016

## **Grading:**

- 10 points = Evidence of improvement  
 5 points = No evidence of improvement  
 0 points = Not done

# Site Specific Template Example *(Version 3)*

Due 2/10/15-2/17/15

<b>Hospital</b>	Hospital x	<b>Measure</b>	Vent Days
<b>TMD</b>	name	<b>Baseline</b>	8.83
<b>TPM</b>	name	<b>Goal Direction (↑ or ↓)</b>	Decrease
<b>PI Staff</b>	name(s)	<b>Cohort</b>	Cohort 2
		<b>Dead: All</b>	Exclude DOA
<b>Registrars</b>	name(s)	<b>ISS</b>	All
		<b>Age</b>	All
		<b>Most recent 12 or 24 mo?</b>	24 months

Due 5/13/15-5/2/15

**Results** 8.33

**List of Actions/Barriers/Progress to Date:**

1. Weaning protocol developed
2. Inservice to RT and nursing
3. Review at PIPS and Systems meetings



# 2016 Performance Index

- New addition of one **“Global”** Metric



- Combined average  
27 centers results
- Working as a Group
- Graded as a Group
- Team Sport





# 2016 Global Measure


- Established problem in trauma
- Meaningful to all centers
- Feasible Do we collect it? Accurately?
- Helpful to centers
  - Kill 2 birds with one stone?
  - Meet a requirement for ACS Reverification?

# 2016 Global Measure Selection Process

- **Timeline**

- Feb 2015: Introduce concept at Feb meeting
- Apr 2015: Solicit ideas from membership/survey
- May 2015: Present ideas list May meeting/discuss  
Resurvey for final ranking of ideas
- Jun 2015: Ensure Registrars Understanding/Training
- Oct 2015: Finalized Oct MTQIP meeting
- Jan 2016: Begin

# BCBSM Abstractor Model



- Increased volume and complexity of MTQIP data
- Increased financial Support from BCBSM
- Starting 2015 increased support from 30% to 80% abstractor position

# MTQIP Clinical Reviewer (MCR)

- RN or equivalent
- Must work on site
- Under the direction of TPM/TMD
- Hiring at the discretion of the TPM/TMD
- Separate position from the trauma registrar
- Does not replace current trauma registry staff
- Performs work required in addition to what current staff are performing

Draft Job Description

# MTQIP Clinical Reviewer (MCR)

- One FTE is required for every 513 cases
- Up to a maximum of 2 FTE's per center
- **Based on volume of submitted cases (1:513)**
- **Additional Support:**
  - \$2,600 annual registry license
  - \$9,000 TQIP membership now paid by MTQIP

# 2015 Implementation Timeline

- Feb:
  - BCBSM letter: ***estimated payment based volume***
- Mar-June
  - Find the best person possible
- June:
  - Payment to hospital
- July:
  - Position in effect

# Making it Work

- Evaluation of implementation
- Signed attestation annually
- If resources not obtained
  - MTQIP membership in jeopardy

# MTQIP Clinical Reviewer (MCR)

**Increased support**

**=**

**Increased expectations**



# The Culture of Safety Event Taxonomy: Overview

## *The Patient Safety Taxonomy*

### **Discloser:**

- This presentation is based on the work of Donald Jenkins, MD & Carol Immermann, RN
- Content from the TOPIC program is being utilized with permission.

# The National Quality Forum Taxonomy

- Recommended as best practice
  - ACS COT PIPS committee
  - ACS VRC leadership
- Inclusion next Optimal Resource book.

# The Problem (Analogy)

Registry  
Data Quality



Poor interrater reliability

PI Program  
Preventable  
Pot preventable  
Non preventable



Poor interrater reliability

# Taxonomy is the Fix

- **Building blocks**
  - Common definitions
  - Clear terminology
- **Scope**
  - Comprehensive tool
  - Applicable to all settings
  - Includes multiple levels of patient harm
- **Addresses:**
  - Sentinel events
  - Adverse events
  - No harm events
  - Near misses
  - Close calls
  - Potential events

# Taxonomy Implementation

- PI process like you normally do
- Examine the “bad case”
- Classify factors according to taxonomy
- Develop computerized application
  - NTDS complications as baseline sentinel events
  - Allow users to add additional sentinel event types

2008 Ivatury  
764 deaths reviewed

The Journal of TRAUMA® Injury, Infection, and Critical Care

## Patient Safety in Trauma: Maximal Impact Management Errors at a Level I Trauma Center

Rao R. Ivatury, MD, FACS, Kelly Guilford, BS, RN, Ajai K. Malhotra, MD, FACS, Therese Duane, MD, FACS, Michel Aboutanos, MD, FACS, and Nancy Martin, MS, RN

**Background:** The Division of Research at JCAHO developed a taxonomy (common terminology and classification schema) to promote consistency in reporting and facilitate root cause analysis. We undertook a review of trauma management errors at our institution with maximal impact (death). The analysis was based on the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) taxonomy.

**Methods:** Trauma deaths between 2001 and 2006 at our Level I trauma center were peer-reviewed to identify errors in

management. The errors are classified according to type, domain, and cause.

**Results:** Seventy-six (9.9%) of 764 deaths had management errors contributing to potentially preventable deaths in 60

in the resuscitative phase. Human errors predominated.

**Conclusions:** Management errors in the basics of trauma care continue even in established trauma centers, despite guidelines, protocols, and continuous performance improvement. Standardized reporting such as the taxonomy may result in progressive collection of patient safety data and lead to innovations to minimize these errors.

**Key Words:** Preventable deaths, Patient safety, Adverse events.

*J Trauma.* 2008;64:265–272.

**Errors:**

**ED**

**OR**

**Resuscitative Phase**

The past 2 decades have witnessed significant accomplishments in the delivery of trauma care in the United


nology and classification schema) to promote consistency in reporting and to facilitate root cause analysis.<sup>3</sup> The National

# Taxonomy

*(Ivatury et al. JT, Feb 2008)*

- **Impact:** Outcome or effect of event
- **Type:** Processes that were faulty
- **Domain:** Setting or phase of care
- **Cause/Factors:** Factors leading to incident
- **Prevention Mitigation:** Universal, selected, action plan

# Framework of the Taxonomy






# Primary Classifications Further Defined

1. **Impact**: the outcomes or effects of medical error and systems failure, commonly referred to as harm to the patient.
2. **Type**: the implied or visible processes that were faulty or failed.
3. **Domain**: the characteristics of the setting in which an incident occurred and the type of individuals involved.
4. **Cause**: the factors and agents that led to an incident.
5. **Prevention and Mitigation**: the measures taken or proposed to reduce the incidence and effects of adverse occurrences.

# Classification: Impact



# Differentiating Levels of Harm

- **None** – patient outcome is not symptomatic or no symptoms detected and no treatment is required (*I. & II. Impact*)
- **Mild** – patient outcome is symptomatic, symptoms are mild, loss of function or harm is minimal or intermediate but short term, and no or minimal intervention (e.g., extra observation, investigation, review or minor treatment) is required (*III. & IV. Impact*)
- **Moderate** – patient outcome is symptomatic, requiring intervention (e.g., additional operative procedure; additional therapeutic treatment), an increased length of stay, or causing permanent or long term harm or loss of function (*V. & VI. Impact*)

# Differentiating Levels of Harm

- **Severe** – patient outcome is symptomatic, requiring life-saving intervention or major surgical/medical intervention, shortening life expectancy or causing major permanent or long term harm or loss of function (*VII. & VIII. Impact*)
- **Death** – on balance of probabilities, death was caused or brought forward in the short term by the incident (*IX. Impact*)


# IMPACT

## Level of Harm to Patient


### Physical

1. No Harm & No Undetectable Harm-Sufficient information determines no harm occurred
2. No Detectable Harm-Insufficient information or unable to determine any harm
3. Minimal-Temporary Harm- Requires little or no intervention
4. Minimal Permanent Harm-Requires initial but not prolonged intervention
5. Moderate-Temporary Harm- Requires initial but not prolonged hospitalization
6. Moderate-Permanent-Harm-Requires intensive but not prolonged hospitalization
7. Severe-Temporary Harm-Requires tx to sustain life but not prolonged hospitalization
8. Severe-Permanent Harm- Requires tx to sustain life and prolonged hospitalization, long-term care, or hospice
9. Death


# Classification: Type



# Classification: Domain




# Classification: Cause





# Classification:

## Prevention (P) & Mitigation (M) [Action Plan]



# Case Study

- 24 y/o male MVC Transfer
- Level III to Level I Center
- Transferred in the evening
- 10 hours post injury
- At request of family

## Level III

- Initially hypotensive
- 5 units PRBCs
- 6 L crystalloid in first 8 hours
- Stable vital signs prior to transfer

# Case Study cont.

## Level I

- Arrives intubated with known pulmonary contusions, rib fractures, open tib/fib fracture, GCS 8, moving all 4 extremities
- Secondary survey & adjunctive studies negative except for suspicion of lower T-spine fracture on CT

# Case Study cont.

- Ortho consult for open tib/fib fracture
  - Requests neuro clearance
- Neuro consult recommends MRI to evaluate T-spine
  - Goes for MRI at 2 am
- During MRI
  - Nurse notes patient cyanotic despite good rhythm on monitor
  - Patient pulled out of scanner- asystole on regular monitor
- CPR, Resuscitated- severe anoxic brain damage
- Support withdrawn 5 days later
- PI review of case found patient had severe base deficit on arrival and collapsed inferior vena cava

# Example Case Taxonomy

- Impact:
  - Medical: Death
  - Non-Medical: Family dissatisfied
  - Non-Medical: Potential litigation
- Type:
  - Communication: Questionable advice
  - Patient Management: Questionable delegation
  - Clinical Management (Intervention): Correct procedure/untimely
- Domain:
  - Setting: Diagnostic procedures
  - Staff: Resident
  - Target: Diagnostic
- Cause:
  - Organizational: Organizational culture
  - Human: Practitioner knowledge

Figure 3. Sample Sentinel Event Tracking Form for Root Cause Analysis

Page 1 of 3

Demographics			
Date of report:	Medical record No.:	Trauma registry No.:	Event date & time:
Nature of event:			
Patient Name:	Age:	Gender:	
Diagnoses:			
Duration of Disease:			
Coexisting Conditions:			
Socioeconomic Status:			
Education:			
Other Pertinent Information:		Report completed by:	
Source of information (✓)			
<input type="checkbox"/> Trauma nurse coordinator	<input type="checkbox"/> PIPS coordinator	<input type="checkbox"/> Conference	
<input type="checkbox"/> Nurse management	<input type="checkbox"/> Patient Relations	<input type="checkbox"/> Registry	
<input type="checkbox"/> Case manager	<input type="checkbox"/> Rounds	<input type="checkbox"/> Other:	
Impact (✓)			
<b>Physical</b> <input type="checkbox"/> No harm <input type="checkbox"/> No detectable harm <input type="checkbox"/> Mild temporary harm <input type="checkbox"/> Mild permanent harm <input type="checkbox"/> Moderate temporary harm <input type="checkbox"/> Moderate permanent harm <input type="checkbox"/> Severe temporary harm <input type="checkbox"/> Severe permanent harm <input type="checkbox"/> Death	<b>Psychological</b> <input type="checkbox"/> No harm <input type="checkbox"/> No detectable harm <input type="checkbox"/> Mild temporary harm <input type="checkbox"/> Mild permanent harm <input type="checkbox"/> Moderate temporary harm <input type="checkbox"/> Moderate permanent harm <input type="checkbox"/> Severe temporary harm <input type="checkbox"/> Severe permanent harm <input type="checkbox"/> Profound mental harm	<b>Legal</b> <input type="checkbox"/> Risk management contacted <input type="checkbox"/> Complaint registered <input type="checkbox"/> Suit filed <input type="checkbox"/> Case dropped <input type="checkbox"/> Case dismissed <input type="checkbox"/> Settled <input type="checkbox"/> Defense Verdict <input type="checkbox"/> Plaintiff Verdict	
<b>Patient/family satisfaction.</b> <input type="checkbox"/> Extremely satisfied <input type="checkbox"/> Satisfied <input type="checkbox"/> Neutral <input type="checkbox"/> Dissatisfied <input type="checkbox"/> Extremely dissatisfied	<b>Social</b> <input type="checkbox"/> Unable to socialize <input type="checkbox"/> Homebound, able to socialize <input type="checkbox"/> No social impediments, not socially active <input type="checkbox"/> Socially active <input type="checkbox"/> Economic	<b>Employment</b> <input type="checkbox"/> Employed <input type="checkbox"/> Seeking employment <input type="checkbox"/> Part-time employment <input type="checkbox"/> Unemployed <input type="checkbox"/> Not employable	

# TJC Taxonomy Via Software

- **Advantages**

- Ease of use
- Improved data collection
- Improved data collation

- **Disadvantages**

- Development time
- Distribution
- Training

# Why Do This?

- Will be able to PI our PI
- Benchmark our PI
- Incorporate into TQIP



# ACSCOT Update

- Connect PIPS with NTDS, NTDB, VRC and TQIP
- Definitions of NQF taxonomy are being 'traumatized'
- NTDB and TQIP input (worked on at EAST)
- Many NTDB and TQIP adverse events have elements that are not defined in the NQF taxonomy (Worked on at EAST)
- Evaluate best practices
- Advise low performing centers on these

# Benchmark Comparison with NTDB

Compare your trauma hospital data with national data

## **Examples:**

- Patient Demographics
- Hospital demographics
- Survivors vs. non-survivors:
  - LOS
  - mean ISS & ICU days
  - Age

## **Examples:**

- Blunt vs. penetrating
- ISS by age group
- Mortality rates
- Mortality by ISS
- ED disposition
- Hospital disposition
- ISS and hospital charge
- Mechanism of injury and restraint usage
- ISS with LOS

# Benchmarks and Measurements: Outcome Data

## **Report Examples:**

- Functional status on discharge (FIM Scores)
- Results of patient satisfaction surveys
- Complication rates
- Compliance with practice management guidelines
- Mortality and morbidity
- Severity-adjusted mortality and morbidity
- Unplanned return to OR
- Unplanned upgrade to an intensive care unit
- Unplanned hospital readmission
- Surgical wound infections
- Organ donation activity

# MTQIP: Proposal

- Request X centers to beta test the process for the COT
- Request COT to assist with costs for MTQIP analysis, software for pulling data over
- Assist registry vendors to providing electronic version
- Provide training to beta test sites

# MTQIP

- Opportunity to be on the front end of what will become the standard
- Opportunity for input on refining definitions or categories for PI



# **Program Coordinator Updates**

**Jill Jakubus, PA-C**



**Website Updates**  
**ArborMetrix Updates**  
**Videos**  
**Data Submission**


**Jill Jakubus, PA-C**





[Reports](#)

# M·TQIP

[HOME](#)[MEMBERSHIP](#)[CALENDAR](#)[RESOURCES](#)[LEADERSHIP](#)[CONTACT US](#)A photograph of a red lighthouse situated on a pier extending into the ocean. The lighthouse is cylindrical with a black lantern room and a small balcony. A black metal walkway with railings leads up to the lighthouse. The sky is overcast with soft clouds, and the water is calm. The pier has a series of black and white buoys extending into the distance.

Dedicated to improving  
the quality of care  
delivered to trauma  
patients in Michigan

# M·TQIP

[HOME](#)

[MEMBERSHIP](#)

[CALENDAR](#)

[RESOURCES](#)

[LEADERSHIP](#)

[CONTACT US](#)



Dedicated to improving  
the quality of care  
delivered to trauma  
patients in Michigan



[Reports](#)

# M·TQIP

[HOME](#)[MEMBERSHIP](#)[CALENDAR](#)[RESOURCES](#)[LEADERSHIP](#)[CONTACT US](#)

## PROGRAM DESIGN

[MEETINGS](#)[REPORTS](#)[FUNDING](#)[REGISTRY](#)[DATA VALIDATION](#)[PI PROJECTS](#)[SITE VISITS](#)

## BECOME A MEMBER

[MEMBERSHIP CRITERIA](#)[GETTING STARTED](#)

## PARTICIPANTS

[RESPONSIBILITIES](#)[ATTENDANCE REQUIREMENTS](#)[MEMBER TRAUMA CENTERS](#)[SELECTED PUBLICATIONS](#)[FAQ](#)

improving  
care  
trauma  
Michigan



# RESOURCES

[HOME](#) > [RESOURCES](#)

## Agreements

- [Data Use Agreement](#)
- [Data Use Agreement Attachment A](#)
- [HIPPA Business Associate Agreement](#)
- [MTQIP Membership Application Form](#)
- [Remote Access Agreement](#)

## FTE Benchmarking

## Data Elements

- [2015 MTQIP Custom Data Elements](#)
- [2014 MTQIP Custom Data Elements](#)

## Education

- [2015 Collection Criteria Grid](#)
- [Antibiotic Reference](#)
- [Hypertension Medication Reference](#)

## Practices

VTE Prophylaxis Outcomes

VTE Prophylaxis Timing

VTE Prophylaxis Types

Hemorrhage

IVC Summary

IVC Trends

TBI Management

Timing of TBI Interventions





## Dashboard // Summary



### Dashboard

Summary

Rankings

Trends

### Outcomes

Summary

Rankings

Trends

Complications Drill-down

Mortality Drill-down

### Utilization

Summary

Rankings

Trends

### Risk Factors

Summary

Rankings

Trends

Comorbidity Drill-down

### Practices

VTE Prophylaxis Outcomes

VTE Prophylaxis Timing

VTE Prophylaxis Types

Hemorrhage

IVC Summary

IVC Trends

TBI Management

Timing of TBI Interventions

### Details

Details

### Administrative

By Hospital Outcomes

By Hospital Process Measures





## Dashboard // Summary

### Dashboard

Summary

Rankings

Trends

### Outcomes

Summary

Rankings

Trends

Complications Drill-down

Mortality Drill-down

### Utilization

Summary

Rankings

Trends

### Risk Factors

Summary

Rankings

Trends

Comorbidity Drill-down

### Practices

VTE Prophylaxis Outcomes

VTE Prophylaxis Timing

VTE Prophylaxis Types

Hemorrhage

IVC Summary

IVC Trends

TBI Management

Timing of TBI Interventions

### Details

Details

### Administrative

By Hospital Outcomes

By Hospital Process Measures

## DEFAULT PERIODS

Program To Date



## COMPARISON GROUPS

MTQIP - All



MTQIP - All

Trauma Center Level 1







FILTERS

HOSPITALS

COHORT

DEAD

NO SIGNS OF LIFE

ISS

AGE

PERIOD GROUP

DEFAULT PERIODS


COMPARISON GROUPS

LEGEND




MTQIP - All

Outcomes Overview



# of Complications





FILTERS

#### HOSPITALS

#### COHORT

#### DEAD

#### NO SIGNS OF LIFE

#### ISS

#### AGE

#### PERIOD GROUP

#### DEFAULT PERIODS


#### COMPARISON GROUPS

LEGEND





MTQIP - All

### Outcomes Overview




### # of Complications





**LEGEND** ■ MTQIP - All ■ Other Hospitals — MTQIP - All ■ 95% Confidence Interval



DVT

TBI MONITOR PLACEMENT  $\leq$  8 HOURS

VTE PROPHYLAXIS WITHIN 48 HOURS



# Hospital Pre-Review Questionnaire

## Payer Mix

Payer	All Patients	Trauma Patients
Commercial	30	40
Medicare	32	22
Medicaid	10	20
HMO/PPO	10	5
Uncompensated/Indigent	11	7
Other including self-pay	7	6

## Hospital Beds

Hospital Beds	Adult	Pediatric	Total
Licensed	600	200	800
Staffed	550	150	700
Average Census	575	175	750

## Level of Response to Activations

Level	Number of Activations	Percent of Total Activations
Highest (Class I)	100	17
Intermediate (Class II)	200	33
Lowest (Class III)	300	50

M·TQIP

Dedicated to improving the quality of care delivered to trauma patients in Michigan

## Michigan Trauma Quality Improvement Program

[Home](#)
[Videos](#)
[Playlists](#)
[Channels](#)
[Discussion](#)
[About](#)

All activities ▾

Michigan Trauma Quality Improvement Program uploaded a video

**Orientation**

**2015 Orientation**

3 weeks ago • 30 views

**1:10:09**

Michigan Trauma Quality Improvement Program uploaded a video

**2015 Definition Updates**

2 months ago • 77 views

2015 Data Dictionary Updates



### ANTIBIOTIC DAYS

The cumulative amount of days the patient received antibiotics administered orally, intravenously or rectally. Each partial or full day of drug or multiple drugs should be measured as one calendar day. Recorded in full days increments with any partial day listed as a full day regardless of purpose of administration

Collection Criterion: Collect on all patients.

Def. Source: MTQIP

Data Base Column Name: MTQIP\_ABX\_DAYS

Type of Field: Custom, Character (Numeric Output)

Length: 1

Report: #1

Name a route of antibiotic administration that should not be captured.

Type your response here

Submit



## MTQIP Central Site

### Data Exchange



[Data Submission](#)

[Submission Review](#)

[Submission Analyzer](#)

### Reporting



[View Reports](#)

[Manage Reports](#)

# Thank you



# Future Meetings

- ◆ Spring (MCOT)

- Wednesday May 13, 2015
- Grand Rapids, Amway Gran Plaza Hotel

- ◆ Spring (Registrars)

- Wednesday June 2, 2015
- Ann Arbor, NCRC

- ◆ Fall

- Tuesday October 13, 2015
- Ypsilanti, EMU Marriott Conference Center

# Conclusion

- ◆ Vote
  - Survey Monkey
  - Three Questions
    - ◆ Region Reports
    - ◆ CME Change
    - ◆ Change to FTE support
- ◆ Evaluations
  - Fill out and turn in